<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pleural fluid analysis in adults with a pleural effusion</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pleural fluid analysis in adults with a pleural effusion</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pleural fluid analysis in adults with a pleural effusion</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John E Heffner, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fabien Maldonado, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thoracentesis with imaging guidance is a bedside or outpatient clinic procedure that permits pleural fluid to be rapidly sampled, visualized, and analyzed for chemical, microbiologic, and cellular content. A systematic approach to analysis of the fluid assists clinicians in narrowing the differential diagnosis or establishing the cause of an effusion. In addition to its diagnostic value, pleural fluid analysis also has predictive value (ie, estimates of the likelihood of a clinical response to pleural fluid drainage) and prognostic value (eg, likelihood of disease recurrence or progression in malignant pleural effusion).</p><p>The initial approach to pleural fluid analysis will be presented here. An initial approach to pleural effusions of uncertain etiology, pleural imaging, and the technique of thoracentesis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6707.html" rel="external">"Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion"</a> and  <a class="medical medical_review" href="/z/d/html/6688.html" rel="external">"Imaging of pleural effusions in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6686.html" rel="external">"Ultrasound-guided thoracentesis"</a>.)</p><p>The diagnostic approach in specific patient populations is also discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8012.html" rel="external">"Tuberculous pleural effusion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6696.html" rel="external">"Etiology, clinical presentation, and diagnosis of chylothorax"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6703.html" rel="external">"Evaluation and management of pleural effusions following cardiac surgery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/119910.html" rel="external">"Pleural effusion of extra-vascular origin (PEEVO)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16317.html" rel="external">"Clinical presentation, diagnosis, and management of cholesterol pleural effusions"</a> and  <a class="medical medical_review" href="/z/d/html/88822.html" rel="external">"Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer", section on 'Pleural (T2, T3, M1a)'</a> and  <a class="medical medical_review" href="/z/d/html/89115.html" rel="external">"Procedures for tissue biopsy in patients with suspected non-small cell lung cancer", section on 'Suspected pleural metastases'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16317.html" rel="external">"Clinical presentation, diagnosis, and management of cholesterol pleural effusions"</a> and  <a class="medical medical_review" href="/z/d/html/88822.html" rel="external">"Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer", section on 'Pleural (T2, T3, M1a)'</a> and  <a class="medical medical_review" href="/z/d/html/89115.html" rel="external">"Procedures for tissue biopsy in patients with suspected non-small cell lung cancer", section on 'Suspected pleural metastases'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16317.html" rel="external">"Clinical presentation, diagnosis, and management of cholesterol pleural effusions"</a> and  <a class="medical medical_review" href="/z/d/html/88822.html" rel="external">"Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer", section on 'Pleural (T2, T3, M1a)'</a> and  <a class="medical medical_review" href="/z/d/html/89115.html" rel="external">"Procedures for tissue biopsy in patients with suspected non-small cell lung cancer", section on 'Suspected pleural metastases'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">"Overview of pleuropulmonary diseases associated with rheumatoid arthritis", section on 'Thoracentesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">"Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Pleural disease'</a>.)</p><p></p><p class="headingAnchor" id="H1024979871"><span class="h1">INDIVIDUALIZING THE APPROACH</span><span class="headingEndMark"> — </span>For all patients with a pleural effusion, we perform initial pleural fluid analysis for the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Routine laboratory biomarkers (all patients). (See <a class="local">'Routine pleural fluid biomarkers'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Specific biomarkers when a specific disease is suspected based on clinical findings or gross fluid appearance. (See <a class="local">'Condition-specific biomarkers'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent <strong>serum</strong> tests, which are needed in some patients. (See <a class="local">'Concurrent serum testing'</a> below.)</p><p></p><p>Our approach considers the likely cause(s) of a pleural effusion and performs a comprehensive assessment early in the process to evaluate those potential causes. In our opinion, this reduces the time to diagnosis, decreases the need for repeat thoracentesis, and leads to prompt management. Several diagnoses can be established definitively by thoracentesis, which are listed on the table  (<a class="graphic graphic_table graphicRef50027" href="/z/d/graphic/50027.html" rel="external">table 1</a>) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Routine pleural fluid biomarkers</span><span class="headingEndMark"> — </span>For every patient with a pleural effusion, we routinely perform all of the following tests on initial pleural fluid samples:</p><p class="bulletIndent1"><span class="glyph">●</span>Cell counts and cell differential (see <a class="local">'Cell counts and cell differential'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Total protein (see <a class="local">'Total protein'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Lactate dehydrogenase (LDH) (see <a class="local">'Lactate dehydrogenase'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Glucose (see <a class="local">'Glucose'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Cholesterol (see <a class="local">'Cholesterol'</a> below)</p><p></p><p>Some experts also perform pleural fluid culture, Gram stain, and cytology, especially when pleural infection or malignancy appear possible diagnoses.</p><p>Some clinicians may not perform pleural fluid cholesterol routinely if they use Light's criteria to classify pleural effusions as exudative or transudative but should order concurrent serum LDH and protein levels instead. (See <a class="local">'Classification as exudative or transudative'</a> below and <a class="local">'Light's criteria (three-test combination rule)'</a> below.)</p><p class="headingAnchor" id="H207219939"><span class="h2">Condition-specific biomarkers</span><span class="headingEndMark"> — </span>In select cases, we perform additional disease-specific biomarkers. We prefer that these be done at the time of the initial thoracentesis when the suspicion is strong enough to warrant them. However, when the suspicion for a specific condition has increased as a result of initial pleural fluid or other testing, some condition-specific biomarkers may be performed on an existing sample, while others may need a repeat thoracentesis. The latter approach is associated with diagnostic delay. For example, it has been shown that it may take a median of 26 days to receive a diagnosis of malignant pleural effusion (MPE) [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H1159114514"><span class="h3">Suspected heart failure-related pleural effusion</span><span class="headingEndMark"> — </span>In patients with pleural effusions suspected to be due to congestive heart failure (CHF), we do not routinely perform additional testing over and above routine tests unless the diagnosis is in doubt.</p><p>CHF-related pleural effusions are typically transudative  (<a class="graphic graphic_table graphicRef73530" href="/z/d/graphic/73530.html" rel="external">table 2</a>). However, 25 to 30 percent of patients with CHF have their pleural effusion misclassified as exudative by combination test criteria, such as Light's criteria (see <a class="local">'Light's criteria (three-test combination rule)'</a> below). This misclassification is thought to be due to performance of thoracentesis after initial diuresis, elevated erythrocytes in the pleural space (the latter increases the LDH level), and/or inherent limitations of approaches to classifying pleural effusions [<a href="#rid3">3-7</a>]. In such cases, we measure the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Albumin or total protein gradient</strong> – Calculation of the serum-to-pleural fluid albumin or protein gradient may help distinguish a transudate from an exudate. (See <a class="local">'Albumin and protein gradients'</a> below.)</p><p></p><p>Although not performed by us, some clinicians also additionally perform pleural fluid N-terminal pro-brain natriuretic peptide (NT-proBNP), although the diagnostic utility is no better than that of serum NT-proBNP. (See <a class="local">'N-terminal pro-BNP'</a> below.)</p><p class="headingAnchor" id="H375741741"><span class="h3">Suspected parapneumonic effusion or empyema</span><span class="headingEndMark"> — </span>For patients with a suspected parapneumonic effusion (eg, cough, fever, radiograph infiltrates), we obtain the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>pH</strong> – Pleural fluid for pH should be drawn directly from the pleural space (typically into an arterial blood gas syringe), placed immediately on ice, and measured within one hour in a blood gas analyzer [<a href="#rid8">8-10</a>]. Of note, mixing pleural fluid with air, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> (from the anesthetic needle or syringe), or an excess of heparin can alter the measured pH. (See <a class="local">'pH'</a> below and  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults", section on 'Thoracentesis and pleural fluid analysis'</a> and  <a class="medical medical_review" href="/z/d/html/6686.html" rel="external">"Ultrasound-guided thoracentesis", section on 'Fluid removal'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gram stain and cultures</strong> – If specific microorganisms are suspected or need to be excluded, special transport tubes and media may be needed (eg, fungal or parasitic cultures). We place a sample of pleural fluid blood cultures bottles and a routine culture tube [<a href="#rid11">11</a>]. When the suspicion for pleural infection is high, antibiotics (or drainage) should not be delayed while waiting for the culture results. (See  <a class="medical medical_review" href="/z/d/html/119384.html" rel="external">"Management and prognosis of parapneumonic pleural effusion and empyema in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytologic staining</strong> – When organisms requiring special stains are suspected or need to be excluded, we send pleural fluid for cytologic immunohistochemical stains (eg, actinomyces, nocardia, fungal).</p><p></p><p>Investigational biomarkers that are not routinely performed include procalcitonin, calprotectin, soluble urokinase plasminogen activator receptor, STREM-1, pleural vascular endothelial growth factor, interleukin 8, and nucleic acid amplification (NAA) for specific organisms [<a href="#rid12">12-15</a>].</p><p>Pleural fluid analysis for the diagnostic evaluation of parapneumonic pleural effusion and empyema is provided separately. (See  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults", section on 'Thoracentesis and pleural fluid analysis'</a>.)</p><p class="headingAnchor" id="H4143743958"><span class="h3">Suspected tuberculous pleural effusion</span><span class="headingEndMark"> — </span>When tuberculous (TB) pleural effusion is suspected (eg, patient with a pleural effusion who lives in an endemic region for TB), we obtain pleural fluid acid fast bacillus (AFB) smear and TB cultures as well as adenosine deaminase (ADA). We do not routinely perform pleural interferon gamma assays or NAA; we reserve NAA for patients in whom the diagnosis is in doubt.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>AFB smear and TB culture</strong> – AFB and TB culture should always be performed since a positive culture is diagnostic. However, AFB and culture results are only positive in less than 50 percent of patients (higher if the fluid is grossly purulent) and may take up to eight weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ADA</strong> – ADA results can be obtained more quickly than culture results and can therefore facilitate a presumptive diagnosis so that therapy can be promptly initiated, when indicated. Measurement of ADA is particularly helpful in regions with a high prevalence of TB and is most useful when the effusion is lymphocyte-predominant and initial AFB smear and culture are negative [<a href="#rid16">16,17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interferon gamma assays</strong> – We do <strong>not</strong> routinely perform pleural fluid interferon gamma assays (eg, T-SPOT.TB and/or QuantiFERON assays) due to the lower cost and ready availability of ADA testing. Waning use has led to their limited availability. While some studies suggest greater diagnostic value of pleural fluid interferon gamma assays in differentiating malignant from TB lymphocytic exudates [<a href="#rid18">18,19</a>], data are limited and report varying diagnostic utility [<a href="#rid20">20-27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NAA</strong> – We do <strong>not</strong> routinely perform NAA testing (eg, Xpert MTB/RIF assay). While some clinicians routinely obtain NAA with AFB, culture and ADA, we reserve NAA testing for patients in whom the diagnosis is not definitive but remains suspected, understanding that it is only US Food and Drug Administration approved for sputum and not for pleural fluid.</p><p></p><p>Further details regarding pleural fluid evaluation and the value of pleural biopsy for the diagnosis of TB pleural effusion are provided separately. (See  <a class="medical medical_review" href="/z/d/html/8012.html" rel="external">"Tuberculous pleural effusion", section on 'Pleural fluid analysis'</a> and  <a class="medical medical_review" href="/z/d/html/6707.html" rel="external">"Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion", section on 'Pleural biopsy'</a>.)</p><p class="headingAnchor" id="H2489500462"><span class="h3">Suspected malignancy</span><span class="headingEndMark"> — </span>For patients with suspected MPE (eg, patient with tobacco exposure who has a large, new-onset pleural effusion), we perform cytology. The approach to patients with suspected pleural metastases from lung cancer is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/88822.html" rel="external">"Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer", section on 'Pleural (T2, T3, M1a)'</a>.)</p><p>In patients with a high suspicion for mesothelioma, we often proceed directly to biopsy since pleural fluid analysis may have a low yield for the diagnosis of mesothelioma [<a href="#rid28">28</a>]. However, many clinicians perform thoracentesis since the diagnosis may not be suspected until later during the evaluation. (See  <a class="medical medical_review" href="/z/d/html/4627.html" rel="external">"Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma", section on 'Diagnosis'</a>.)</p><p>For patients with suspected lymphoma or multiple myeloma, we also obtain flow cytometry and immunohistochemical staining, which, if positive, may help support the diagnosis [<a href="#rid29">29-31</a>]. (See  <a class="medical medical_review" href="/z/d/html/4686.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma", section on 'Flow cytometry/immunohistochemistry'</a>.)</p><p>We do not perform other cancer biomarkers (eg, carcinogenic embryonic antigen). (See <a class="local">'Cytology, flow cytometry, and cancer-related biomarkers'</a> below.)</p><p class="headingAnchor" id="H1856228522"><span class="h3">Suspected pancreatic- or esophageal rupture-related effusion</span><span class="headingEndMark"> — </span>When pancreatic-related pleural effusion is suspected, we obtain pleural fluid pancreatic amylase (eg, chronic pancreatitis and a right-sided pleural effusion). When esophageal rupture is suspected, we obtain salivary amylase and pleural fluid pH (eg, patient with recurrent or violent vomiting and a pleural effusion). (See <a class="local">'Amylase'</a> below and <a class="local">'pH'</a> below.)</p><p class="headingAnchor" id="H1428925956"><span class="h3">Suspected chylous or cholesterol effusion</span><span class="headingEndMark"> — </span>A cholesterol pleural effusion may be suspected in a patient with risk factors (eg, chronic TB or rheumatoid pleuritis, milky fluid on gross appearance  (<a class="graphic graphic_table graphicRef121783" href="/z/d/graphic/121783.html" rel="external">table 3</a>)) while chylothorax may be suspected in patients with a separate group of risk factors (eg, trauma, malignant tumors of the mediastinum, lymphangioleiomyomatosis, milky fluid on gross appearance  (<a class="graphic graphic_table graphicRef61456" href="/z/d/graphic/61456.html" rel="external">table 4</a>)). In both scenarios, we typically obtain cholesterol and triglyceride levels. Rarely, fluid may be needed for lipoprotein analysis to determine the presence of chylomicrons (usually performed on a second thoracentesis or from fluid stored in the laboratory). (See <a class="local">'Cholesterol'</a> below and <a class="local">'Triglycerides'</a> below.)</p><p class="headingAnchor" id="H2007162306"><span class="h3">Suspected rheumatoid or lupus pleuritis</span><span class="headingEndMark"> — </span>In patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) who have a pleural effusion that is suspected to be due to the underlying disorder (ie, pleuritis), we typically request the following:</p><p class="bulletIndent1"><span class="glyph">●</span>RA – Cytology for tadpole cells and laboratory analysis of rheumatoid factor</p><p class="bulletIndent1"><span class="glyph">●</span>SLE – Cytology for lupus erythematosus cells (if available) and antinuclear antibody testing</p><p></p><p>Of note, most clinical laboratories no longer perform lupus erythematosus preparation tests, which are lengthy and complex and are considered by some experts as having low diagnostic utility [<a href="#rid32">32,33</a>]. Interpreting these studies is discussed below. (See <a class="local">'Connective tissue disease biomarkers'</a> below.)</p><p class="headingAnchor" id="H3310189905"><span class="h3">Suspected hemothorax</span><span class="headingEndMark"> — </span>When hemothorax is suspected, we perform a hematocrit on a fresh sample of pleural fluid ("pleurocrit") and collect it into a complete blood count (ie, lavender top) tube. Diagnosing hemothorax is discussed below. (See <a class="local">'Cell counts and cell differential'</a> below.)</p><p class="headingAnchor" id="H4224924065"><span class="h3">Others</span><span class="headingEndMark"> — </span>Other markers may be useful when specific conditions are suspected. For example, pleural effusions of extravascular origin may require specific biomarkers  (<a class="graphic graphic_table graphicRef122224" href="/z/d/graphic/122224.html" rel="external">table 5</a>) (see  <a class="medical medical_review" href="/z/d/html/119910.html" rel="external">"Pleural effusion of extra-vascular origin (PEEVO)"</a>). Most of these conditions are typically rare but include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Suspected urinothorax – Creatinine (concurrent serum creatinine level needed)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspected ventriculoperitoneal or ventriculopleural shunt-related effusion – Beta-2-transferrin</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspected glycinothorax (eg, glycine bladder washout) – Glycine (concurrent serum glycine level needed)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspected bilothorax – Bilirubin (concurrent serum bilirubin level needed)</p><p></p><p class="headingAnchor" id="H3482632522"><span class="h2">Concurrent serum testing</span><span class="headingEndMark"> — </span>Concurrent <strong>serum</strong> tests are needed in the following patients:</p><p class="bulletIndent1"><span class="glyph">●</span>If planning to use Light's criteria to distinguish exudative from transudative pleural effusions, blood should be drawn for total protein and LDH so that comparative measurements with pleural fluid levels can be made. No blood tests are needed if classification rules are used that require only pleural fluid bioassays. (See <a class="local">'Light's criteria (three-test combination rule)'</a> below and <a class="local">'Pleural fluid only three-test combination (PFO3)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a specific condition is suspected that requires comparative analysis of pleural fluid and serum biomarkers, corresponding blood testing should be performed (eg, red cell count [hemothorax], amylase [ruptured esophagus, pancreatic effusion], creatinine [urinothorax], bilirubin [bilothorax]  (<a class="graphic graphic_table graphicRef122224" href="/z/d/graphic/122224.html" rel="external">table 5</a>)).</p><p></p><p class="headingAnchor" id="H3900923378"><span class="h1">INTERPRETING PLEURAL FLUID FINDINGS</span></p><p class="headingAnchor" id="H965552115"><span class="h2">Gross appearance</span><span class="headingEndMark"> — </span>Initial diagnostic clues can be obtained by gross inspection of pleural fluid as it is being aspirated from the patient's chest [<a href="#rid1">1</a>]. Observations that are helpful diagnostically are listed in the table  (<a class="graphic graphic_table graphicRef74757" href="/z/d/graphic/74757.html" rel="external">table 6</a>). Gross features may also facilitate the inclusion of additional pleural fluid biomarkers for both diagnostic and prognostic purposes. As examples, it is appropriate to do the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Turbid fluid – Draw a pH and perform microbiologic testing</p><p class="bulletIndent1"><span class="glyph">●</span>Milky fluid – Assay for lipids and cholesterol</p><p class="bulletIndent1"><span class="glyph">●</span>Bloody fluid – Obtain a hematocrit ("pleurocrit") and cytology</p><p class="bulletIndent1"><span class="glyph">●</span>Black fluid – Perform fungal and bacterial cultures, amylase, cytology, and hematocrit</p><p class="bulletIndent1"><span class="glyph">●</span>Green fluid – bilirubin, cytology, and rheumatoid factor</p><p></p><p class="headingAnchor" id="H1078101168"><span class="h2">Classification as exudative or transudative</span><span class="headingEndMark"> — </span>Once routine biomarkers have been measured, we classify the pleural effusion as either a transudate or an exudate. This distinction is important since etiologies of transudates  (<a class="graphic graphic_table graphicRef73530" href="/z/d/graphic/73530.html" rel="external">table 2</a>) and exudates  (<a class="graphic graphic_table graphicRef54055" href="/z/d/graphic/54055.html" rel="external">table 7</a>) differ from one another.</p><p>However, despite this dichotomous classification, most experts recognize that overlap exists and the distinction can be challenging when the pleural fluid test results are borderline or when pleural tests are discordant with each other or with the clinical suspicion. Clinicians should understand that existing approaches have considerable limitations. Rather than accepting test result classifications as definitive, we interpret test results in the context of the patient's clinical findings and consider how much they alter the pretest probability of an exudate. (See <a class="local">'Our approach'</a> below and <a class="local">'Alternate approaches'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transudates</strong> – Transudates result from imbalances in hydrostatic and oncotic pressures in the chest in patients with congestive heart failure (CHF), liver failure, and nephrosis. They can also be due to conditions external to the pleural space (eg, peritoneal, cerebrospinal fluid) or to iatrogenic conditions (eg, crystalloid infusion through a central venous catheter that has migrated into the mediastinum or pleural space). Transudates have a limited number of diagnostic possibilities that can usually be discerned from the patient's clinical presentation  (<a class="graphic graphic_table graphicRef73530" href="/z/d/graphic/73530.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exudates</strong> – In contrast, exudative effusions present more of a diagnostic challenge. Disease in virtually any organ can cause exudative pleural effusions by a variety of mechanisms, including infection, malignancy, immunologic responses, lymphatic abnormalities, noninfectious inflammation, iatrogenic causes, and movement of fluid from below the diaphragm (eg, acute or chronic pancreatitis, chylous ascites, and peritoneal carcinomatosis)  (<a class="graphic graphic_table graphicRef54055" href="/z/d/graphic/54055.html" rel="external">table 7</a>).</p><p></p><p class="bulletIndent1">Exudates result primarily from pleural and lung inflammation (resulting in increased entry of fluid and protein due to elevated capillary permeability), impaired lymphatic drainage of the pleural space (resulting in a decreased removal of pleural fluid and protein), or movement of fluid from the peritoneal space.</p><p></p><p>Approaches used to distinguish transudative from exudative pleural effusions, including our approach, and caveats associated with approaches in general, are reviewed below. (See <a class="local">'Our approach'</a> below and <a class="local">'Alternate approaches'</a> below and <a class="local">'Limitations of one-, two-, and three-test classification systems'</a> below.)</p><p class="headingAnchor" id="H3867236553"><span class="h3">Our approach</span><span class="headingEndMark"> — </span>Several approaches have been described to help classify pleural fluid as transudative or exudative. Our approach is the following:</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with a pleural effusion who need pleural fluid analysis, we favor the "pleural fluid only" three-test combination rule (PFO<sub>3</sub>) that measures pleural fluid protein, cholesterol, and lactate dehydrogenase (LDH) and does not require serum tests (<a class="calc calc_professional" href="/z/d/html/139616.html" rel="external">calculator 1</a>). The rationale for this preference, description of the calculation, and comparison with Light’s criteria are discussed below. (See <a class="local">'Pleural fluid only three-test combination (PFO3)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As alternatives, Light's criteria (a three-test combination rule that requires concurrent serum tests (<a class="calc calc_professional" href="/z/d/html/130621.html" rel="external">calculator 2</a>)), two-test combinations, and one-test rules are also appropriate. (See <a class="local">'Light's criteria (three-test combination rule)'</a> below and <a class="local">'One- and two-test classification rules'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When pleural fluid test results are discordant (eg, one criterion classifies the fluid as exudative while others classify it as transudative) or borderline or a classification result does not fit the clinical context (eg, an exudate in a patient with heart failure), we use a Bayesian approach that uses likelihood ratios (LRs) to derive a more precise estimate of the posttest probability of an exudate (<a class="calc calc_professional" href="/z/d/html/139614.html" rel="external">calculator 3</a> and <a class="calc calc_professional" href="/z/d/html/139615.html" rel="external">calculator 4</a>). Bayesian approaches incorporate a patient's clinical context (ie, pretest probability of an exudate) to help clinicians avoid placing too much reliance on dichotomous approaches that can only classify pleural fluid as either exudative or transudative regardless of clinical context. (See <a class="local">'Borderline or discordant results: Bayesian approaches'</a> below.)</p><p></p><p>Data to support using any particular classification approach over another are limited. One meta-analysis of eight studies (1448 patients) examined multiple pleural fluid tests and combinations of tests to distinguish exudates from transudates and found that all individual tests except for one (pleural fluid bilirubin) had similar accuracy [<a href="#rid34">34</a>]. Another meta-analysis demonstrated similar classification accuracy between Light's criteria and several individual pleural fluid tests [<a href="#rid35">35</a>]. A single center database report found similar classification accuracies of several single and combination classification strategies analyzed [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1525591644"><span class="h4">Pleural fluid only three-test combination (PFO3)</span><span class="headingEndMark"> — </span>We use PFO<sub>3</sub>, a three-test combination approach (<a class="calc calc_professional" href="/z/d/html/139616.html" rel="external">calculator 1</a>), as our preferred calculation [<a href="#rid34">34,36</a>]. A pleural effusion is considered an exudate if any one or more of the following are present:</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural fluid protein greater than 3.0 g/dL (30 g/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural fluid cholesterol greater than 55 mg/dL (1.424 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural fluid LDH greater than 0.67 times the upper limit of the laboratory's normal serum LDH</p><p></p><p class="bulletIndent2">Our preference for PFO<sub>3</sub> is based on the advantages of obviating a need for blood sampling and avoiding the duplicative use of highly correlated criteria (eg, pleural fluid LDH and pleural fluid-to-serum LDH ratios as found in Light's criteria) and data that report a similar accuracy to the traditional approach of Light's criteria [<a href="#rid34">34,36</a>].</p><p></p><p>Reports vary in the cutoff value used for pleural fluid cholesterol being between 45 to 55 mg/dL and pleural fluid LDH greater than 0.45 to 0.67 upper limits of normal [<a href="#rid34">34,36,37</a>]. Cutoff values have even varied within these ranges when reported from the same institution and investigative group at different times [<a href="#rid36">36,37</a>], demonstrating inherent imprecisions in identifying perfect cutoff points because of spectrum bias from differences in patient characteristics in different settings and times. The original derivation of PFO<sub>3</sub> from a large meta-analysis proposed the following cutoff points: pleural fluid protein &gt;2.9 g/dL, pleural fluid LDH &gt;0.45 upper limits of normal, and pleural fluid cholesterol &gt;45 mg/dL [<a href="#rid34">34</a>]. We use the cutoff values listed above because they derive from the largest (5299 patients) and most updated dataset from a single center that showed equal diagnostic accuracy of PFO<sub>3</sub> compared with Light's criteria [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H4097730132"><span class="h3">Alternate approaches</span></p><p class="headingAnchor" id="H329650380"><span class="h4">Light's criteria (three-test combination rule)</span><span class="headingEndMark"> — </span>The Light's Criteria Rule is a commonly used three-test rule that measures serum and pleural fluid protein and LDH (<a class="calc calc_professional" href="/z/d/html/130621.html" rel="external">calculator 2</a>) [<a href="#rid38">38</a>].</p><p>According to the Light's Criteria Rule, if at least one of the following three criteria (ie, component tests of the rule) is fulfilled, the fluid is defined as an exudate [<a href="#rid38">38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural fluid-to-serum protein ratio greater than 0.5</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural fluid-to-serum LDH ratio greater than 0.6</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural fluid LDH greater than 0.67 (ie, two-thirds) the upper limits of the laboratory's normal serum LDH</p><p></p><p>Light's criteria have been criticized for including pleural fluid LDH in two separate criteria (ie, pleural fluid LDH and pleural fluid-to-serum LDH ratio) [<a href="#rid34">34</a>], which means that the two criteria are highly correlated, which decreases its diagnostic accuracy [<a href="#rid34">34,37,39</a>]. In addition, use of pleural fluid-to-serum ratios require simultaneous blood tests that increase costs and inconvenience to the patient. Data also suggest that omitting the pleural fluid-to-serum LDH ratio does not diminish the diagnostic accuracy of Light's criteria [<a href="#rid3">3,36</a>] or other two-test rules that also include pleural fluid-to-serum LDH ratio [<a href="#rid40">40</a>].</p><p>Light's criteria have a high sensitivity but a moderate specificity for exudative pleural effusions [<a href="#rid36">36,41</a>]. As a result, 25 to 30 percent of transudates are incorrectly classified as exudates, particularly those due to heart failure when diuretics are given or a high level of erythrocytes (which release LDH) are present in the pleural fluid [<a href="#rid36">36,40,42</a>]. Despite a high sensitivity, up to 10 percent of pleural effusions due to malignancy are classified as transudates by Light's criteria [<a href="#rid43">43,44</a>], although it is unclear whether this is from the inherent imperfection of all classification systems or the fact that some malignant effusions are transudates due to various mechanisms (eg, superior vena cava obstruction).</p><p class="headingAnchor" id="H774435716"><span class="h4">One- and two-test classification rules</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleural fluid only</strong> <strong>two-test combination rule (PFO</strong><strong><sub>2</sub></strong><strong>)</strong> – Multiple studies have examined the discriminative properties of two-test combination rules for classifying pleural effusions that variably included pleural fluid cholesterol, protein, or LDH in various pair-wise combinations using different cutoff points for pleural fluid cholesterol and LDH [<a href="#rid35">35,36,40,45</a>]. If a two-test combination is to be used, we prefer using the following rule that classifies an effusion as exudative when one or both criteria are met [<a href="#rid40">40</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pleural fluid cholesterol greater than 40 mg/dL (1.034 mmol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>Pleural fluid LDH greater than 0.60 times the upper limit of the laboratory's normal serum LDH</p><p></p><p class="bulletIndent1">In support, one study reported that these criteria had an overall accuracy equivalent to Light's criteria (area under the receiver operating curve 0.87 versus 0.85, respectively) and had the advantage of avoiding blood draws [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>One-test criteria</strong> – Limited data suggest that some single tests have sufficient accuracy when used <strong>individually</strong> to classify pleural effusion as exudative. As examples [<a href="#rid35">35</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pleural fluid cholesterol greater than 55 mg/dL (1.424 mmol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>Pleural fluid-to-serum cholesterol ratio greater than 0.3</p><p class="bulletIndent2"><span class="glyph">•</span>Pleural fluid LDH greater than 200 U/L</p><p class="bulletIndent2"><span class="glyph">•</span>Total protein concentrations above 3.0 g/dL (30 g/L)</p><p class="bulletIndent2"><span class="glyph">•</span>Pleural fluid LDH greater than 0.67 times the upper limit of the laboratory's normal serum LDH</p><p></p><p class="bulletIndent1">Although the optimal cutoff point reported for pleural fluid LDH that indicates an exudate varies [<a href="#rid46">46</a>] with cutoffs ranging from 45 percent to 83 percent of the laboratory's upper limit of normal [<a href="#rid34">34,36,47,48</a>], most experts use a cutoff of greater than 0.67 (ie, two-thirds) the upper limits of the laboratory's normal serum LDH.</p><p></p><p class="bulletIndent1">Several studies have examined the diagnostic sensitivity of one-test rules. One meta-analysis reported that when pleural fluid cholesterol greater than 55 mg/dL (1.424 mmol/L), pleural fluid-to-serum cholesterol ratio &gt;0.3, and pleural fluid LDH greater than 200 U/L were used as a single-test criterion, each had only slightly lower sensitivities but higher specificities as compared with Light's criteria [<a href="#rid35">35</a>]. Other studies report a similar lower sensitivity and higher specificity when compared with two-test and three-test combination strategies [<a href="#rid34">34,36</a>]. However, confidence intervals of the overall diagnostic accuracy of each of these tests overlapped so none appeared clearly superior to any other.</p><p></p><p class="bulletIndent1">For patients with suspected heart failure who have an atypical presentation and whose pleural effusion is suspected to be misclassified as an exudate, we use either one of the following single-test criteria to help recategorize the pleural effusion as a <strong>transudate</strong> [<a href="#rid3">3,49</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum-to-pleural fluid albumin gradient (ie, the difference between the serum and pleural values) greater than 1.2 g/dL (12 g/L)</p><p class="bulletIndent2"><span class="glyph">•</span>Serum-to-pleural fluid protein gradient greater than 2.5 g/dL (25 g/L)</p><p></p><p class="bulletIndent1">For such patients, it is unclear if the albumin or protein serum-to-pleural fluid gradients add to clinical decision-making over and above information gained from other assessments of cardiac performance, such as serum N-terminal pro-BNP (NT-proBNP) and echocardiography. (See <a class="local">'Albumin and protein gradients'</a> below and <a class="local">'N-terminal pro-BNP'</a> below.)</p><p></p><p class="headingAnchor" id="H442508752"><span class="h3">Limitations of one-, two-, and three-test classification systems</span><span class="headingEndMark"> — </span>When interpreting pleural fluid biomarkers, it is important for the clinician to understand that cutoff points for pleural fluid test results are chosen intentionally to maximize sensitivity for exudates because the identification of exudative effusions has considerable prognostic importance (eg, cancer and parapneumonic effusion). However, this comes at the price of lowering the specificity because sensitivity and specificity are inversely coupled for all diagnostic tests (ie, as sensitivity increases, specificity decreases) [<a href="#rid41">41,50</a>]. Further increasing sensitivity at the expense of specificity is the commonly used classification strategy that combines two or more tests in "either-or" rules wherein only one component test result needs to be positive to make the rule positive. This results in the sensitivity of the combination test rule being higher than the sensitivity of the individual component tests of the rule, but the specificity of the rule is lower than its individual components [<a href="#rid50">50</a>]. This tradeoff of higher sensitivity for lower specificity is considered "desirable" since it is important that exudates not be missed. Some transudates, however, may be misclassified as an exudate because of the decreased specificity of the combination test rule [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/2759.html" rel="external">"Glossary of common biostatistical and epidemiological terms"</a>.)</p><p>However, these classification systems all treat test results that are marginally close to cutoff points (eg, protein 3 g/dL [borderline]) the same as results that are at the extreme range of the test (eg, protein 7 g/dL [extreme]) (see <a class="local">'Pleural fluid only three-test combination (PFO3)'</a> above and <a class="local">'Light's criteria (three-test combination rule)'</a> above and <a class="local">'One- and two-test classification rules'</a> above) [<a href="#rid52">52</a>] and, as a consequence, may misclassify pleural fluid as exudates or transudates when values are near their cutoff points [<a href="#rid34">34,36,37,50,53</a>]. A meta-analysis demonstrated that even though the overall diagnostic accuracy of Light's criteria is &gt;90 percent in most studies, diagnostic accuracy falls to 70 percent when any of the three criteria return results close to their cutoff points [<a href="#rid53">53</a>]. We use a Bayesian approach in such cases to help inform the likelihood of an exudate within a specific clinical context. (See <a class="local">'Borderline or discordant results: Bayesian approaches'</a> below.)</p><p class="headingAnchor" id="H790479118"><span class="h3">Borderline or discordant results: Bayesian approaches</span><span class="headingEndMark"> — </span>Bayesian approaches use LRs and clinician pretest estimates (ie, pretest probability) to help inform them of the likelihood that a pleural effusion is an exudate by calculating a posttest probability. Rather than classifying effusions as exudates or transudates (ie, a dichotomous classification), a Bayesian approach removes this dichotomization and allows clinicians to combine their gestalt clinical suspicion that the patient has an exudate (high [eg, 90 percent], moderate/uncertain [eg, 50 percent], or low [eg, 10 percent]) with the pleural fluid test results to calculate a posttest probability of an exudate.</p><p class="bulletIndent1">Dichotomous and continuous LRs for pleural fluid tests have been described for use in calculators. We prefer calculators that use continuous LRs since they are easier to use and likely more precise (<a class="calc calc_professional" href="/z/d/html/139614.html" rel="external">calculator 3</a> and <a class="calc calc_professional" href="/z/d/html/139615.html" rel="external">calculator 4</a>):</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continuous LRs – Two studies have reported simple exponential equations for common pleural fluid tests that can be built into calculators to compute a unique LR for every discrete value across a test result's range (ie, continuous LR) [<a href="#rid37">37,53</a>]. This process gives clinicians a more precise estimate as to how much the pleural fluid test results increase or decrease the pretest estimate of the probability of an exudate than can be achieved by dichotomous approaches (eg, Light's or PFO<sub>3</sub>) and is our preferred Bayesian approach (<a class="calc calc_professional" href="/z/d/html/139614.html" rel="external">calculator 3</a> and <a class="calc calc_professional" href="/z/d/html/139615.html" rel="external">calculator 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dichotomous LRs – Several studies have reported dichotomous LRs for common pleural fluid tests, although the cutoff values for each test differ among studies [<a href="#rid34">34-36,40,52</a>]. These LRs may be used in dichotomous calculators that allow computation of posttest probabilities with LRs derived from multiple test results (<a class="calc calc_professional" href="/z/d/html/13434.html" rel="external">calculator 5</a>).</p><p></p><p>Bayesian approaches using either dichotomous or continuous LRs help clinicians recognize that pleural fluid test values that fall only slightly above or below a single cutoff point marginally alter their pretest estimates of the probability of an exudate. Clinicians may use calculators based on continuous LRs for the PFO<sub>3</sub> rule pleural fluid test values (<a class="calc calc_professional" href="/z/d/html/139615.html" rel="external">calculator 4</a>) or Light's criteria (<a class="calc calc_professional" href="/z/d/html/139614.html" rel="external">calculator 3</a>) rules. (See  <a class="medical medical_review" href="/z/d/html/2759.html" rel="external">"Glossary of common biostatistical and epidemiological terms"</a>.)</p><p class="headingAnchor" id="H4021713783"><span class="h2">Interpreting individual biomarkers</span><span class="headingEndMark"> — </span>Individual pleural fluid biomarkers should be interpreted in the clinical context to help narrow the differential. Specific biomarker patterns together with clinical and imaging findings can lead to a diagnosis in the majority of patients  (<a class="graphic graphic_table graphicRef139766" href="/z/d/graphic/139766.html" rel="external">table 8</a>).</p><p class="headingAnchor" id="H1429919042"><span class="h3">Cell counts and cell differential</span><span class="headingEndMark"> — </span>We typically evaluate both the white cell count and differential as well as the red cell count.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>White cell count and differential</strong> – Because of associated challenges in collecting the small amount of pleural fluid that is present in healthy individuals, few studies have determined normal values for the white cell count and differential. However, one study in healthy adults that collected pleural fluid by lavage reported that the pleural fluid white cell count was &lt;2000/microL, with a predominance of macrophages (approximately 75 percent) and lymphocytes (approximately 23 percent) [<a href="#rid54">54</a>]. Mesothelial cell, neutrophil, and eosinophil counts comprised the remainder (&lt;1 percent each).</p><p></p><p class="bulletIndent1">An elevated white cell count is typically encountered with pleural injury, inflammation, or infection. Timing influences the predominant cell type. For example, the early cellular response to pleural injury is neutrophilic. However, as the time from the acute pleural insult lengthens, the effusion develops a mononuclear predominance, provided that the pleural injury is not ongoing.</p><p></p><p class="bulletIndent1">When assessing pleural fluid for the white cell count and differential, we consider the following approach reasonable:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Polymorphonuclear-predominant pleural effusion</strong> – The total pleural fluid nucleated cell count is virtually never diagnostic of a single entity. There are, however, some settings in which specific levels may have diagnostic importance [<a href="#rid55">55-57</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Counts above 50,000/microL in an exudative pleural effusion are usually found only in complicated parapneumonic effusions, including empyema.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Counts above 10,000/microL in an exudative pleural effusion are typically due to bacterial pneumonia, acute pancreatitis, and lupus pleuritis.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Counts below 5000/microL are likely due to chronic exudates such as tuberculous (TB) pleurisy and malignancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphocyte-predominant pleural effusion</strong> – Elevated lymphocyte content in pleural fluid may indicate a reactive or benign condition or a neoplasm [<a href="#rid1">1,58-61</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Lymphocyte counts representing 85 to 95 percent of the total nucleated cells suggests TB pleurisy or lymphoma (primary pleural lymphoma or systemic lymphoma) and, less commonly, sarcoidosis, chronic rheumatoid pleurisy, yellow nail syndrome, chylothorax, or drug-induced pleural effusion. (See  <a class="medical medical_review" href="/z/d/html/8012.html" rel="external">"Tuberculous pleural effusion"</a> and  <a class="medical medical_review" href="/z/d/html/4752.html" rel="external">"Primary effusion lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/6696.html" rel="external">"Etiology, clinical presentation, and diagnosis of chylothorax"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Malignant pleural effusions (MPEs; other than lymphoma) are lymphocyte-predominant in over one-half of cases; however, the percentage of lymphocytes is usually between 50 and 70 percent.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Some viral- and drug-induced pleural effusions are lymphocyte predominant (eg, dasatinib-related).</p><p></p><p class="bulletIndent2">Cytomorphologic examination of lymphocytes provides an essential clue to the underlying disease. Small versus large lymphocytes, cellular atypia, and a history of lymphoma warrant the initiation of specialized studies, such as immunophenotyping and molecular assays to exclude cancer [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eosinophilic pleural effusion</strong> – Pleural fluid eosinophilia (defined by pleural fluid eosinophils representing more than 10 percent of the total nucleated cells) occurs with both malignant and benign etiologies [<a href="#rid63">63</a>]. The differential diagnosis of pleural fluid eosinophilia is listed in the table  (<a class="graphic graphic_table graphicRef82213" href="/z/d/graphic/82213.html" rel="external">table 9</a> and <a class="graphic graphic_table graphicRef72026" href="/z/d/graphic/72026.html" rel="external">table 10</a>) [<a href="#rid63">63-66</a>] and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6704.html" rel="external">"Pleural fluid eosinophilia"</a>.)</p><p></p><p class="bulletIndent2">Eosinophils &gt;15 percent may support a diagnosis of malignancy [<a href="#rid63">63,67-69</a>] and may decrease the likelihood of TB pleurisy in the absence of pneumothorax [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent2">Eosinophilia may have prognostic significance. One study reported that lung cancer patients with pleural fluid eosinophilia had a better prognosis than those without eosinophilia [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Basophilia</strong> – Basophils greater than 10 percent of nucleated cells suggests leukemic involvement of the pleura [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mesothelial cells</strong> – Mesothelial cells are found in small numbers in normal pleural fluid, are prominent in transudative pleural effusions, and are variable in exudative effusions. The major clinical significance of mesothelial cells in exudates is that tuberculosis is unlikely if there are more than 5 percent mesothelial cells [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Red cell count</strong> – Evidence of red blood cells (RBCs) in pleural fluid may reflect minor bleeding due to traumatic thoracentesis or inflammation. However, large amounts of RBCs may reflect hemothorax. The ratio of pleural fluid to blood hematocrit &gt;0.5 is considered diagnostic of hemothorax. However, if patients undergo thoracentesis several days after active bleeding stops, some patients with hemothorax have values between 25 to 50 percent [<a href="#rid72">72,73</a>].</p><p></p><p class="bulletIndent1">Patients with heart failure may have pleural fluid erythrocyte counts &gt;10,000 cells/microL causing a serosanguinous appearance and artifactual elevation of pleural fluid LDH measurement, thereby misclassifying the effusion as exudative [<a href="#rid74">74</a>].</p><p></p><p class="headingAnchor" id="H4068358357"><span class="h3">Total protein</span><span class="headingEndMark"> — </span>The major reason for measuring the protein level in pleural fluid is to determine whether the fluid is exudative or transudative (see <a class="local">'Classification as exudative or transudative'</a> above). However, specific levels may have some diagnostic value. For example:</p><p class="bulletIndent1"><span class="glyph">●</span>TB pleural effusions virtually always have total protein concentrations above 4.0 g/dL (40 g/L) [<a href="#rid75">75</a>]. (See <a class="local">'Suspected tuberculous pleural effusion'</a> above and  <a class="medical medical_review" href="/z/d/html/8012.html" rel="external">"Tuberculous pleural effusion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very high pleural fluid protein concentrations (eg, 7.0 to 8.0 g/dL [70 to 80 g/L]) may suggest Waldenström macroglobulinemia and multiple myeloma [<a href="#rid76">76,77</a>]. (See  <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"</a> and  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extremely low pleural fluid concentrations (eg, &lt;1 g/dL) suggest migration of a central venous infusion catheter or ventriculoperitoneal shunt into the pleural space, duro-pleural fistula, peritoneal dialysate, glycinothorax, hepatic hydrothorax, or urinothorax [<a href="#rid78">78,79</a>](See  <a class="medical medical_review" href="/z/d/html/119910.html" rel="external">"Pleural effusion of extra-vascular origin (PEEVO)"</a>.)</p><p></p><p class="headingAnchor" id="H4259076286"><span class="h3">Lactate dehydrogenase</span><span class="headingEndMark"> — </span>The level of pleural fluid LDH is one of the key criteria for differentiating transudates from exudates (See <a class="local">'Classification as exudative or transudative'</a> above.)</p><p></p><p>Several specific disease associations have been noted with elevated pleural fluid LDH levels:</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural fluid LDH levels above 1000 international units (IU/L with upper limit of normal for serum of 200 IU/L) are characteristically found in empyema [<a href="#rid80">80,81</a>], rheumatoid pleurisy [<a href="#rid82">82</a>], pleural paragonimiasis [<a href="#rid83">83</a>], and sometimes malignancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pleural fluid LDH levels are elevated in both TB pleural effusions and complicated parapneumonic pleural effusions (empyema), but values are lower in TB effusions (365 U/L versus 4037 U/L) [<a href="#rid84">84</a>], providing diagnostic value in discriminating between these two conditions [<a href="#rid81">81,85</a>]. (See <a class="local">'Suspected tuberculous pleural effusion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pleural fluid-to-serum LDH ratio greater than 1.0 and a pleural fluid-to-serum protein ratio of less than 0.5 is characteristic of <em>Pneumocystis jirovecii</em> [<a href="#rid86">86</a>] but can also be seen in malignancy, coronavirus disease 2019 (COVID-19) [<a href="#rid87">87</a>], and urinothorax [<a href="#rid88">88</a>]. (See <a class="local">'Others'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While in the past, pleural fluid LDH levels above 1000 IU/L have been proposed to predict the need for chest tube drainage for patients with parapneumonic effusions, data are limited and do not support this claim [<a href="#rid89">89</a>].</p><p></p><p class="headingAnchor" id="H612795208"><span class="h3">Glucose</span><span class="headingEndMark"> — </span>Most pleural effusions have a pleural glucose level similar to that of blood. However, select conditions should be considered when the glucose level is low or high.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low pleural fluid glucose</strong> – A low pleural fluid glucose concentration (less than 60 mg/dL [3.33 mmol/liter]) or a pleural fluid-to-serum glucose ratio less than 0.5 narrows the differential diagnosis of the exudate to the following possibilities [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rheumatoid pleurisy</p><p class="bulletIndent2"><span class="glyph">•</span>Complicated parapneumonic effusion or empyema</p><p class="bulletIndent2"><span class="glyph">•</span>MPE</p><p class="bulletIndent2"><span class="glyph">•</span>TB pleurisy</p><p class="bulletIndent2"><span class="glyph">•</span>Lupus pleuritis</p><p class="bulletIndent2"><span class="glyph">•</span>Esophageal rupture</p><p class="bulletIndent2"><span class="glyph">•</span>Normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> infusate</p><p class="bulletIndent2"><span class="glyph">•</span>Urinothorax</p><p></p><p class="bulletIndent1">The lowest glucose concentrations are found in rheumatoid pleurisy and empyema, with glucose being undetectable in some cases. In comparison, when the glucose concentration is low in TB pleurisy, lupus pleuritis, and malignancy, it usually falls into the range of 30 to 50 mg/dL (1.66 to 2.78 mmol/L) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">The mechanism responsible for a low pleural fluid glucose depends on the underlying disease. Specific examples include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased diffusion of glucose from blood to pleural fluid with rheumatoid pleurisy [<a href="#rid90">90,91</a>] or malignancy [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased utilization of glucose by constituents of pleural fluid, such as neutrophils, bacteria (empyema), and malignant cells [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High pleural fluid glucose</strong> – Transudative pleural effusions with elevated pleural fluid glucose concentrations may be secondary to a misplaced central venous catheter that infuses glucose-containing fluids into the pleural space [<a href="#rid78">78</a>] or to migration of peritoneal dialysate fluid from the intraperitoneal space into the pleural space [<a href="#rid94">94</a>]. (See <a class="local">'Others'</a> above.)</p><p></p><p class="headingAnchor" id="H1812828679"><span class="h3">pH</span><span class="headingEndMark"> — </span>When interpreting pH, we suggest the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal pH</strong> – The pH of normal human pleural fluid inferred from animal models is approximately 7.60 [<a href="#rid95">95</a>]. Transudates generally have a pleural fluid pH in the 7.40 to 7.55 range, while the majority of exudates range from 7.30 to 7.45 [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low pH</strong> – A pleural fluid pH below 7.30 with a normal arterial blood pH is found in patients with the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute lupus pleuritis</p><p class="bulletIndent2"><span class="glyph">•</span>MPE</p><p class="bulletIndent2"><span class="glyph">•</span>Complicated parapneumonic effusions/empyema</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic rheumatoid pleural effusions</p><p class="bulletIndent2"><span class="glyph">•</span>Urinothorax</p><p class="bulletIndent2"><span class="glyph">•</span>TB pleural effusions</p><p class="bulletIndent2"><span class="glyph">•</span>Pancreatic-pleural fistula</p><p class="bulletIndent2"><span class="glyph">•</span>Hemothorax</p><p class="bulletIndent2"><span class="glyph">•</span>Inadvertent intrapleural infusion of normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a></p><p class="bulletIndent2"><span class="glyph">•</span>Esophageal rupture</p><p class="bulletIndent2"><span class="glyph">•</span>Crystalloid infusion into the pleural space</p><p></p><p class="bulletIndent1">Inadvertent infusion of normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and urinothorax are the only transudates that can have a pleural fluid pH &lt;7.40 [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/z/d/html/119910.html" rel="external">"Pleural effusion of extra-vascular origin (PEEVO)"</a>.)</p><p></p><p class="bulletIndent1">A low pleural fluid pH has not only diagnostic but also therapeutic implications for patients with parapneumonic effusions [<a href="#rid97">97</a>]. As an example, a parapneumonic effusion with a low pleural fluid pH (≤7.15) indicates a high likelihood of necessity for pleural space drainage [<a href="#rid89">89,98-100</a>]. The differential diagnosis of pleural fluid acidosis and implications for patients with a parapneumonic pleural effusion are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults", section on 'Thoracentesis and pleural fluid analysis'</a> and  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1">A low pleural fluid pH also has prognostic and therapeutic implications for patients with MPE [<a href="#rid97">97</a>]. Patients with MPE who have a low pleural fluid pH have a high initial positive yield on pleural fluid cytology. They also tend to have a shorter survival and poorer response to chemical pleurodesis than those with a pH &gt;7.30, [<a href="#rid101">101-103</a>]. However, we do not use a low pleural fluid pH as a criterion for the decision to forego pleurodesis since the strength of these associations are weak [<a href="#rid102">102,103</a>]. (See  <a class="medical medical_review" href="/z/d/html/6700.html" rel="external">"Management of malignant pleural effusions"</a>.)</p><p></p><p class="bulletIndent1">The mechanisms responsible for pleural fluid acidosis (pH &lt;7.30) include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased acid production by pleural fluid cells and bacteria (empyema) [<a href="#rid93">93,104</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Migration of urine or infusion via misplaced catheters of low pH solutions (eg, normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) into the pleural space.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High pH</strong> – A high pleural fluid pH greater than the normal pleural fluid pH of 7.60 is usually due to sample error if the sample was not placed on ice or not immediately analyzed. Rarely, it may be associated with a misplaced catheter that is infusing bicarbonate or pleural space infection caused by urea-splitting organisms, such as <em>Proteus</em> species [<a href="#rid105">105</a>].</p><p></p><p class="headingAnchor" id="H3191780846"><span class="h3">N-terminal pro-BNP</span><span class="headingEndMark"> — </span>An NT-proBNP level &gt;1500 pg/mL supports the presence of a transudative pleural effusion consistent with heart failure [<a href="#rid3">3,4</a>].</p><p>However, routinely measuring pleural fluid NT-proBNP has questionable value since it correlates well with serum values for NT-proBNP [<a href="#rid106">106-108</a>]. Meta-analyses report that the overall sensitivity and specificity of pleural fluid NT-proBNP for CHF was greater than 90 percent each [<a href="#rid107">107,109</a>]; however, measuring it in the blood was equally as effective [<a href="#rid107">107</a>]. (See  <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure"</a>.)</p><p>False positives can occur. For example, patients with septic shock or acute kidney injury can elevate NT-proBNP and, thereby, lower the specificity of NT-proBNP (73 percent) [<a href="#rid110">110</a>]. In addition, patients with true exudates due to parapneumonic effusions or MPEs may have elevated pleural fluid levels of NT-proBNP possibly from coexisting heart failure [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H1187644737"><span class="h3">Albumin and protein gradients</span><span class="headingEndMark"> — </span>In patients with heart failure, a serum-to-pleural fluid albumin gradient (ie, the difference between the serum and pleural values) greater than 1.2 g/dL (12 g/L) or a serum-to-pleural fluid total protein gradient &gt;2.5 g/dL supports a transudative effusion [<a href="#rid3">3,6,111</a>]. One study reported that acute diuresis increased the concentration of all pleural fluid components, but the impact of albumin and protein gradients was lower than on individual components [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H2188939187"><span class="h3">Microbiologic Gram stain and cultures</span><span class="headingEndMark"> — </span>Positive Gram stain and cultures are generally diagnostic of a parapneumonic effusion, and frank pus is diagnostic of empyema. (See  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H1763029650"><span class="h3">Acid fast smear and tuberculous cultures</span><span class="headingEndMark"> — </span>While acid fast smear can be positive for TB and non-TB mycobacteria, positive TB culture is definitively diagnostic. However, cultures can take up to eight weeks to become positive and are imperfect since less than 50 percent of patients are actually positive.</p><p class="headingAnchor" id="H3613609040"><span class="h3">Adenosine deaminase</span><span class="headingEndMark"> — </span>The most common diagnostic threshold used to establish a TB pleural effusion is a pleural fluid adenosine deaminase (ADA) level greater than 40 U/L [<a href="#rid17">17</a>]. The level of ADA is typically greater than 35 U/L in TB pleural effusions [<a href="#rid112">112</a>], and TB is rare when the ADA level is less than 40 U/L (ie, a high negative predictive value) [<a href="#rid113">113</a>]. However, the clinician should be aware that false-negative and false-positive results can occur (eg, malignancy, mesothelioma, lymphoma, uremic pleuritis, human immunodeficiency virus [HIV] infection, hemorrhagic effusions, empyema, rheumatoid pleurisy, and immunoglobulin G4-related pleural disease) [<a href="#rid112">112,114,115</a>]. Further details are provided separately. (See  <a class="medical medical_review" href="/z/d/html/8012.html" rel="external">"Tuberculous pleural effusion", section on 'Pleural fluid analysis'</a>.)</p><p class="headingAnchor" id="H781391259"><span class="h3">Cytology, flow cytometry, and cancer-related biomarkers</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytology</strong> – Cytologic analysis of pleural fluid can establish the diagnosis of MPEs but has an overall sensitivity of approximately 60 percent [<a href="#rid116">116,117</a>], which may increase by 15 percent with a second thoracentesis sample [<a href="#rid118">118</a>]. Identification of benign etiologies may be evident on cytologic staining (eg, microorganisms and lymphangioleiomyomatosis).</p><p></p><p class="bulletIndent1">The sensitivity of pleural fluid cytology for malignancy varies depending on the histologic type of the underlying cancer. One meta-analysis reported that pleural fluid cytology has a sensitivity of 85 percent for ovarian cancer, 78 to 83 percent for adenocarcinoma, 65 percent for breast cancer, 53 percent for small cell carcinoma, 29 percent for mesothelioma, and 25 percent for squamous cell carcinomas [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent1">We prefer to collect a sufficient volume of pleural fluid to enhance the diagnostic yield of cytology and allow examination of a cell block [<a href="#rid119">119</a>]. High-quality studies to determine the minimum volume of submitted sample for accurate diagnosis are limited and report differing results [<a href="#rid120">120-125</a>]. Nonetheless, based on existing data, we send at least 75 mL for cytology, especially in the era of molecular profiling [<a href="#rid126">126</a>]. While the College of Pathologists guideline recommends sending as much fluid as is possible [<a href="#rid125">125</a>], even small volumes of pleural fluid can yield a diagnosis [<a href="#rid127">127</a>].</p><p></p><p class="bulletIndent1">One factor that has complicated cytologic reporting for pleural fluid is the variation in the descriptions of diagnostic terminology. To standardize terminology, cytology experts have published the "International System for Reporting Serous Fluid Cytopathology" [<a href="#rid128">128</a>].</p><p></p><p class="bulletIndent1">Further details on the value to pleural fluid analysis for the diagnosis of lung cancer are provided separately. (See  <a class="medical medical_review" href="/z/d/html/88822.html" rel="external">"Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer", section on 'Pleural (T2, T3, M1a)'</a> and  <a class="medical medical_review" href="/z/d/html/89115.html" rel="external">"Procedures for tissue biopsy in patients with suspected non-small cell lung cancer", section on 'Thoracentesis-cytology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flow cytometry</strong> – For patients with suspected lymphoma (primary pleural or systemic), flow cytometry and immunohistochemical staining may supplement cytology that identifies lymphomatous cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational cancer-related biomarkers</strong> – Clinical applicability of cancer-related biomarkers to establish a diagnosis of pleural malignancy is limited by the lack of standardized laboratory analysis methodologies and a shortage of studies that validate positive studies. No single pleural fluid biomarker is accurate enough for routine use in the diagnostic evaluation of pleural effusion [<a href="#rid129">129,130</a>]. The role of soluble mesothelin-related peptides in the diagnosis of pleural mesothelioma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4627.html" rel="external">"Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma", section on 'Biomarkers under investigation'</a>.)</p><p></p><p class="headingAnchor" id="H3203571346"><span class="h3">Amylase</span><span class="headingEndMark"> — </span>An amylase-rich pleural effusion is defined as either a pleural fluid amylase greater than the upper limits of normal for serum amylase or a pleural fluid-to-serum amylase ratio &gt;2. When present, this narrows the differential diagnosis of an exudative effusion to the following major possibilities:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute pancreatitis</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic pancreatitis</p><p class="bulletIndent1"><span class="glyph">●</span>Esophageal rupture</p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy</p><p></p><p>Other rare causes of an amylase-rich pleural effusion include pneumonia, ruptured ectopic pregnancy, multiple myeloma, hydronephrosis, and cirrhosis [<a href="#rid131">131,132</a>].</p><p>Pancreatic disease is associated with the pancreatic isoenzyme while malignancy and esophageal rupture are characterized by a predominance of the salivary isoenzyme [<a href="#rid131">131</a>]. Esophageal rupture is also associated with a very low pH (often as low as 6) and ingested vegetable or meat fragments on cytology.</p><p>Pleural fluid amylase, however, has low discriminative value for differentiating benign from malignant effusions, so it is not routinely performed in suspected cancer for this reason.</p><p class="headingAnchor" id="H1976168669"><span class="h3">Cholesterol</span><span class="headingEndMark"> — </span>Pleural cholesterol can be used for the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Classifying exudative from transudative pleural effusions – Measurement of pleural cholesterol has been used to differentiate transudative from exudative effusions. Elevated pleural cholesterol is included in the one-, two-, and three-test classification rules [<a href="#rid34">34</a>]. (See <a class="local">'One- and two-test classification rules'</a> above and <a class="local">'Pleural fluid only three-test combination (PFO3)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of cholesterol pleural effusion – An elevated cholesterol &gt;250 mg/dL defines a cholesterol effusion (also known as pseudochylothorax or chyliform effusion)  (<a class="graphic graphic_algorithm graphicRef131055" href="/z/d/graphic/131055.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/16317.html" rel="external">"Clinical presentation, diagnosis, and management of cholesterol pleural effusions", section on 'Diagnosis'</a>.)</p><p></p><p>The presence of cholesterol in pleural fluid is thought to be derived from degenerating cells and vascular leakage from increased permeability.</p><p class="headingAnchor" id="H2705209252"><span class="h3">Triglycerides</span><span class="headingEndMark"> — </span>An exudative pleural effusion with elevated triglyceride concentration greater than 110 mg/dL supports the diagnosis of a chylothorax. A level less than 50 mg/dL excludes a chylothorax with reasonable likelihood, and an intermediate level between 50 and 110 mg/dL should be followed by lipoprotein analysis of the pleural fluid for chylomicrons  (<a class="graphic graphic_algorithm graphicRef131056" href="/z/d/graphic/131056.html" rel="external">algorithm 2</a>) [<a href="#rid133">133</a>]. (See  <a class="medical medical_review" href="/z/d/html/6696.html" rel="external">"Etiology, clinical presentation, and diagnosis of chylothorax", section on 'Pleural fluid analysis'</a>.)</p><p>Patients with transudates and elevated triglyceride levels typically have hepatic cirrhosis, nephrotic syndrome, amyloidosis, or obstruction of the superior vena cava [<a href="#rid134">134,135</a>].</p><p class="headingAnchor" id="H2999458045"><span class="h3">Connective tissue disease biomarkers</span><span class="headingEndMark"> — </span>For patients with connective tissue disease, interpreting pleural fluid cytologic and antibody findings may help differentiate rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) associated pleural effusion due to <strong>pleuritis</strong> from pleural effusion due to other causes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>RA</strong> – In patients with RA, cytologic evidence of elongated macrophages and distinctive multinucleated giant cells (tadpole cells) in a background of amorphous debris and the presence of rheumatoid factor in pleural fluid may be supportive of the diagnosis of rheumatoid pleuritis. However, the sensitivity and specificity of these findings have not been described. (See  <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">"Overview of pleuropulmonary diseases associated with rheumatoid arthritis", section on 'Thoracentesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SLE</strong> – A pleural fluid antinuclear antibody (ANA) titer ≥1:160 is a sensitive tool (86 to 100 percent) for detecting lupus pleuritis in patients with a known diagnosis of SLE [<a href="#rid136">136-140</a>]. One study of 59 patients, 16 of whom had underlying lupus, reported a sensitivity of 91 percent, specificity of 83 percent, and negative predictive value of 97 percent for an ANA &gt;1:80 in discriminating lupus from nonlupus pleuritis-related pleural effusion [<a href="#rid141">141</a>].</p><p></p><p class="bulletIndent1">While in the past, positive pleural fluid lupus erythematosus cell preparation tests, pleural fluid ANA titers ≥1:160, and a pleural fluid-to-serum ANA ratio ≥1 were considered diagnostic of lupus pleuritis, it is now apparent none of these findings occurs solely in lupus pleuritis. For example, lupus erythematosus cells have been identified in patients with malignancy and RA [<a href="#rid32">32,142,143</a>]. Similarly, small case series report that pleural fluid ANA titer ≥1:160 can be found in exudative, parapneumonic and malignancy-associated effusions [<a href="#rid136">136-139</a>]. Even an extremely high pleural fluid ANA &gt;1:640 can occur in malignant effusions [<a href="#rid139">139</a>].</p><p></p><p class="bulletIndent1">Using the ratio of pleural fluid-to-serum ANA of ≥1 [<a href="#rid136">136,138,139</a>] or ANA staining pattern in pleural fluid does not provide any additional diagnostic value for the diagnosis of lupus pleuritis [<a href="#rid137">137,139</a>]. (See  <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">"Pulmonary manifestations of systemic lupus erythematosus in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3300941580"><span class="h3">Others</span><span class="headingEndMark"> — </span>The interpretation of other parameters such as creatinine (urinothorax), beta-2 transferrin (ventriculoperitoneal shunt), pleural fluid-to-serum glucose ratio (peritoneal dialysate pleural effusion), pleural fluid-to-serum bilirubin (bilothorax), and glycine (glycinothorax) can be found in the table  (<a class="graphic graphic_table graphicRef122224" href="/z/d/graphic/122224.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/119910.html" rel="external">"Pleural effusion of extra-vascular origin (PEEVO)"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">FINALIZING A DIAGNOSIS</span><span class="headingEndMark"> — </span>In most patients, a diagnosis can be achieved using an approach that combines clinical evaluation with pleural fluid analysis targeted at the suspected underlying disorder  (<a class="graphic graphic_table graphicRef139766" href="/z/d/graphic/139766.html" rel="external">table 8</a>). This evaluation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6707.html" rel="external">"Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion"</a> and  <a class="medical medical_review" href="/z/d/html/6707.html" rel="external">"Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion", section on 'Additional evaluation for unclear etiology'</a>.)</p><p class="headingAnchor" id="H1018584325"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112226.html" rel="external">"Society guideline links: Pleural effusion"</a>.)</p><p class="headingAnchor" id="H7170464"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/17200.html" rel="external">"Patient education: Pleural effusion (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4650.html" rel="external">"Patient education: Thoracentesis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H365048"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>What tests to order</strong> – When deciding what tests to order in patients undergoing thoracentesis, we keep the following principles in mind:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Routine</strong> – In all patients, we perform pleural fluid analysis for routine laboratory tests including white and red cell count and differential, total protein, lactate dehydrogenase (LDH), glucose, and cholesterol. Some experts also perform pleural fluid culture, Gram stain, and cytology especially when pleural infection or malignancy appear possible diagnoses. (See <a class="local">'Routine pleural fluid biomarkers'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Condition-specific tests</strong> – When a specific disease is suspected based upon clinical findings or gross fluid appearance  (<a class="graphic graphic_table graphicRef74757" href="/z/d/graphic/74757.html" rel="external">table 6</a>), we additionally perform specific biomarkers at the time of initial pleural fluid sampling (eg, triglycerides, cytology, Gram stain and culture, amylase, rheumatoid factor, bilirubin, creatinine, beta-2-transferrin). (See <a class="local">'Condition-specific biomarkers'</a> above and <a class="local">'Gross appearance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory blood draws</strong> – When Light's criteria are being used to differentiate transudative from exudative effusion, we draw blood for total protein and LDH. We draw other laboratory tests if specific conditions listed in the table  (<a class="graphic graphic_table graphicRef122224" href="/z/d/graphic/122224.html" rel="external">table 5</a>) are suspected (eg, cell count [hemothorax], amylase [ruptured esophagus, pancreatic effusion], creatinine [urinothorax], bilirubin [bilothorax]). (See <a class="local">'Condition-specific biomarkers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distinguishing transudates and exudates</strong> – This distinction is important since etiologies of transudates  (<a class="graphic graphic_table graphicRef73530" href="/z/d/graphic/73530.html" rel="external">table 2</a>) and exudates  (<a class="graphic graphic_table graphicRef54055" href="/z/d/graphic/54055.html" rel="external">table 7</a>) differ from one another. Data to support using any particular classification approach over another are limited and conflicting. (See <a class="local">'Classification as exudative or transudative'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pleural fluid only three-test combination rule (PFO</strong><strong><sub>3</sub></strong><strong>)</strong> – For most patients with a pleural effusion of unclear etiology, we favor the PFO<sub>3</sub> rule that measures pleural fluid protein, cholesterol, and LDH (<a class="calc calc_professional" href="/z/d/html/139616.html" rel="external">calculator 1</a>). Our preference for PFO<sub>3</sub> is based on the advantages of obviating the need for blood sampling and avoiding the duplicative use of highly correlated criteria (ie, pleural fluid LDH and pleural fluid-to-serum LDH ratio) and data that suggest a similar sensitivity to the traditional approach of Light's criteria. (See <a class="local">'Pleural fluid only three-test combination (PFO3)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternative rules</strong> – As alternatives, Light's criteria (a three-test combination rule that requires concurrent serum tests (<a class="calc calc_professional" href="/z/d/html/130621.html" rel="external">calculator 2</a>)), two-test combinations, and one-test rules are also appropriate. (See <a class="local">'Alternate approaches'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bayesian approach</strong> – When pleural fluid test results are borderline or discordant with each other or with the clinical suspicion, we use calculators that use continuous likelihood ratios to derive a more precise estimate of the posttest probability of an exudate (<a class="calc calc_professional" href="/z/d/html/139614.html" rel="external">calculator 3</a> and <a class="calc calc_professional" href="/z/d/html/139615.html" rel="external">calculator 4</a>). (See <a class="local">'Borderline or discordant results: Bayesian approaches'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individual pleural fluid biomarkers</strong> – Individual pleural fluid biomarkers should be interpreted in the clinical context to help narrow the differential. Occasionally, additional testing may be needed to confirm or exclude a diagnosis. Common diagnoses that are made using this approach are listed in the tables  (<a class="graphic graphic_table graphicRef122224" href="/z/d/graphic/122224.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef139766" href="/z/d/graphic/139766.html" rel="external">table 8</a>). (See <a class="local">'Interpreting individual biomarkers'</a> above and <a class="local">'Finalizing a diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – Further evaluation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6707.html" rel="external">"Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion", section on 'Additional evaluation for unclear etiology'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sahn SA, Huggins JT, San Jose E, et al. The art of pleural fluid analysis. Clin Pulm Med 2013; 20:77.</a></li><li><a class="nounderline abstract_t">Tsim S, Paterson S, Cartwright D, et al. Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups. Lung Cancer 2019; 133:123.</a></li><li><a class="nounderline abstract_t">Porcel JM, Ferreiro L, Civit C, et al. Development and validation of a scoring system for the identification of pleural exudates of cardiac origin. Eur J Intern Med 2018; 50:60.</a></li><li><a class="nounderline abstract_t">Korczyński P, Górska K, Konopka D, et al. Significance of congestive heart failure as a cause of pleural effusion: Pilot data from a large multidisciplinary teaching hospital. Cardiol J 2020; 27:254.</a></li><li><a class="nounderline abstract_t">Chakko SC, Caldwell SH, Sforza PP. Treatment of congestive heart failure. Its effect on pleural fluid chemistry. Chest 1989; 95:798.</a></li><li><a class="nounderline abstract_t">Romero-Candeira S, Fernández C, Martín C, et al. Influence of diuretics on the concentration of proteins and other components of pleural transudates in patients with heart failure. Am J Med 2001; 110:681.</a></li><li><a class="nounderline abstract_t">Ferreiro L, Porcel JM, Valdés L. Diagnosis and Management of Pleural Transudates. Arch Bronconeumol 2017; 53:629.</a></li><li><a class="nounderline abstract_t">Cheng DS, Rodriguez RM, Rogers J, et al. Comparison of pleural fluid pH values obtained using blood gas machine, pH meter, and pH indicator strip. Chest 1998; 114:1368.</a></li><li><a class="nounderline abstract_t">Bowling M, Lenz P, Chatterjee A, et al. Perception versus reality: the measuring of pleural fluid pH in the United States. Respiration 2012; 83:316.</a></li><li><a class="nounderline abstract_t">Rahman NM, Mishra EK, Davies HE, et al. Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose. Am J Respir Crit Care Med 2008; 178:483.</a></li><li><a class="nounderline abstract_t">Menzies SM, Rahman NM, Wrightson JM, et al. Blood culture bottle culture of pleural fluid in pleural infection. Thorax 2011; 66:658.</a></li><li><a class="nounderline abstract_t">Davies J. Procalcitonin. J Clin Pathol 2015; 68:675.</a></li><li><a class="nounderline abstract_t">Lee SH, Lee EJ, Min KH, et al. Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion. Clin Biochem 2013; 46:1484.</a></li><li><a class="nounderline abstract_t">Zou MX, Zhou RR, Wu WJ, et al. The use of pleural fluid procalcitonin and C-reactive protein in the diagnosis of parapneumonic pleural effusions: a systemic review and meta-analysis. Am J Emerg Med 2012; 30:1907.</a></li><li><a class="nounderline abstract_t">He C, Wang B, Li D, et al. Performance of procalcitonin in diagnosing parapneumonic pleural effusions: A clinical study and meta-analysis. Medicine (Baltimore) 2017; 96:e7829.</a></li><li><a class="nounderline abstract_t">Liang QL, Shi HZ, Wang K, et al. Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis. Respir Med 2008; 102:744.</a></li><li><a class="nounderline abstract_t">Aggarwal AN, Agarwal R, Sehgal IS, et al. Meta-analysis of Indian studies evaluating adenosine deaminase for diagnosing tuberculous pleural effusion. Int J Tuberc Lung Dis 2016; 20:1386.</a></li><li><a class="nounderline abstract_t">Liu YC, Shin-Jung Lee S, Chen YS, et al. Differential diagnosis of tuberculous and malignant pleurisy using pleural fluid adenosine deaminase and interferon gamma in Taiwan. J Microbiol Immunol Infect 2011; 44:88.</a></li><li><a class="nounderline abstract_t">Kalantri Y, Hemvani N, Chitnis DS. Evaluation of real-time polymerase chain reaction, interferon-gamma, adenosine deaminase, and immunoglobulin A for the efficient diagnosis of pleural tuberculosis. Int J Infect Dis 2011; 15:e226.</a></li><li><a class="nounderline abstract_t">Klimiuk J, Safianowska A, Chazan R, et al. Development and Evaluation of the New Predictive Models in Tuberculous Pleuritis. Adv Exp Med Biol 2015; 873:53.</a></li><li><a class="nounderline abstract_t">Meldau R, Peter J, Theron G, et al. Comparison of same day diagnostic tools including Gene Xpert and unstimulated IFN-γ for the evaluation of pleural tuberculosis: a prospective cohort study. BMC Pulm Med 2014; 14:58.</a></li><li><a class="nounderline abstract_t">Liu F, Gao M, Zhang X, et al. Interferon-gamma release assay performance of pleural fluid and peripheral blood in pleural tuberculosis. PLoS One 2013; 8:e83857.</a></li><li><a class="nounderline abstract_t">Pang CS, Shen YC, Tian PW, et al. Accuracy of the interferon-gamma release assay for the diagnosis of tuberculous pleurisy: an updated meta-analysis. PeerJ 2015; 3:e951.</a></li><li><a class="nounderline abstract_t">Zhang L, Zhang Y, Shi X, et al. Utility of T-cell interferon-γ release assays for diagnosing tuberculous serositis: a prospective study in Beijing, China. PLoS One 2014; 9:e85030.</a></li><li><a class="nounderline abstract_t">Aggarwal AN, Agarwal R, Gupta D, et al. Interferon Gamma Release Assays for Diagnosis of Pleural Tuberculosis: a Systematic Review and Meta-Analysis. J Clin Microbiol 2015; 53:2451.</a></li><li><a class="nounderline abstract_t">Aggarwal AN, Agarwal R, Dhooria S, et al. Pleural fluid tumor necrosis factor for diagnosis of pleural tuberculosis: A systematic review and meta-analysis. Cytokine 2021; 141:155467.</a></li><li><a class="nounderline abstract_t">Tong X, Li Z, Zhao J, et al. The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy. Trop Med Int Health 2021; 26:1356.</a></li><li><a class="nounderline abstract_t">Segal A, Sterrett GF, Frost FA, et al. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology:  results of a 20 year audit. Pathology 2013; 45:44.</a></li><li><a class="nounderline abstract_t">AbdullGaffar B, Seliem R. Anaplastic diffuse large B-cell lymphoma cytologically diagnosed in pleural effusion: Report of two cases. Diagn Cytopathol 2021; 49:E307.</a></li><li><a class="nounderline abstract_t">Alkan O, Tiryaki TO, Kalayoglu-Besisik S. Myelomatous Pleural Effusion: A Rare Involvement in Myeloma. J Med Cases 2020; 11:55.</a></li><li><a class="nounderline abstract_t">Gupta P, Pandey T, Gautam U, et al. Lymphoreticular malignancies in serous effusions: Cytomorphologic, flow cytometric and immunocytochemical analysis. Diagn Cytopathol 2021; 49:647.</a></li><li><a class="nounderline abstract_t">Bouros D, Pneumatikos I, Tzouvelekis A. Pleural involvement in systemic autoimmune disorders. Respiration 2008; 75:361.</a></li><li><a class="nounderline abstract_t">Ferreiro L, Alvarez-Dobaño JM, Valdés L. Systemic diseases and the pleura. Arch Bronconeumol 2011; 47:361.</a></li><li><a class="nounderline abstract_t">Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Primary Study Investigators. Chest 1997; 111:970.</a></li><li><a class="nounderline abstract_t">Wilcox ME, Chong CA, Stanbrook MB, et al. Does this patient have an exudative pleural effusion? The Rational Clinical Examination systematic review. JAMA 2014; 311:2422.</a></li><li><a class="nounderline abstract_t">Porcel JM, Light RW. Pleural Fluid Analysis: Are Light's Criteria Still Relevant After Half a Century? Clin Chest Med 2021; 42:599.</a></li><li><a class="nounderline abstract_t">Porcel JM, Peña JM, Vicente de Vera C, et al. Bayesian analysis using continuous likelihood ratios for identifying pleural exudates. Respir Med 2006; 100:1960.</a></li><li><a class="nounderline abstract_t">Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972; 77:507.</a></li><li><a class="nounderline abstract_t">Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med 2004; 66:411.</a></li><li><a class="nounderline abstract_t">Lépine PA, Thomas R, Nguyen S, et al. Simplified Criteria Using Pleural Fluid Cholesterol and Lactate Dehydrogenase to Distinguish between Exudative and Transudative Pleural Effusions. Respiration 2019; 98:48.</a></li><li><a class="nounderline abstract_t">Heffner JE. Discriminating between transudates and exudates. Clin Chest Med 2006; 27:241.</a></li><li><a class="nounderline abstract_t">Porcel JM, Martínez-Alonso M, Cao G, et al. Biomarkers of heart failure in pleural fluid. Chest 2009; 136:671.</a></li><li><a class="nounderline abstract_t">Gonlugur TE, Gonlugur U. Transudates in malignancy: still a role for pleural fluid. Ann Acad Med Singap 2008; 37:760.</a></li><li><a class="nounderline abstract_t">Ashchi M, Golish J, Eng P, O'Donovan P. Transudative malignant pleural effusions: prevalence and mechanisms. South Med J 1998; 91:23.</a></li><li><a class="nounderline abstract_t">Porcel JM, Vives M, Vicente de Vera MC, et al. Useful tests on pleural fluid that distinguish transudates from exudates. Ann Clin Biochem 2001; 38:671.</a></li><li><a class="nounderline abstract_t">Eigsti RL, Krasowski MD, Vidholia A, Merrill AE. Review of interference indices in body fluid specimens submitted for clinical chemistry analyses. Pract Lab Med 2020; 19:e00155.</a></li><li><a class="nounderline abstract_t">Porcel JM, Vives M. Classic, abbreviated, and modified Light's criteria: the end of the story? Chest 1999; 116:1833.</a></li><li><a class="nounderline abstract_t">Vives M, Porcel JM, Vicente de Vera M, et al. A study of Light's criteria and possible modifications for distinguishing exudative from transudative pleural effusions. Chest 1996; 109:1503.</a></li><li><a class="nounderline abstract_t">Porcel JM. Identifying transudates misclassified by Light's criteria. Curr Opin Pulm Med 2013; 19:362.</a></li><li><a class="nounderline abstract_t">Heffner JE. Evaluating diagnostic tests in the pleural space. Differentiating transudates from exudates as a model. Clin Chest Med 1998; 19:277.</a></li><li><a class="nounderline abstract_t">Kummerfeldt CE, Chiuzan CC, Huggins JT, et al. Improving the predictive accuracy of identifying exudative effusions. Chest 2014; 145:586.</a></li><li><a class="nounderline abstract_t">Heffner JE, Sahn SA, Brown LK. Multilevel likelihood ratios for identifying exudative pleural effusions(*). Chest 2002; 121:1916.</a></li><li><a class="nounderline abstract_t">Heffner JE, Highland K, Brown LK. A meta-analysis derivation of continuous likelihood ratios for diagnosing pleural fluid exudates. Am J Respir Crit Care Med 2003; 167:1591.</a></li><li><a class="nounderline abstract_t">Noppen M, De Waele M, Li R, et al. Volume and cellular content of normal pleural fluid in humans examined by pleural lavage. Am J Respir Crit Care Med 2000; 162:1023.</a></li><li><a class="nounderline abstract_t">Cedrés S, Torrejon D, Martínez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 2012; 14:864.</a></li><li><a class="nounderline abstract_t">Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 2012; 7:587.</a></li><li><a class="nounderline abstract_t">Popowicz N, Cheah HM, Gregory C, et al. Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance. PLoS One 2021; 16:e0250628.</a></li><li><a class="nounderline abstract_t">Ferreiro L, San-José E, Suárez-Antelo J, Valdés L. Dasatinib-induced pleural effusion: Chylothorax, an option to consider. Ann Thorac Med 2016; 11:289.</a></li><li><a class="nounderline abstract_t">Cantley RL, Hrycaj S, Konopka K, et al. Cytologic findings in effusions from patients with SARS-CoV-2 infection. J Am Soc Cytopathol 2021; 10:261.</a></li><li><a class="nounderline abstract_t">Elis A, Mulchanov I, Radnay J, et al. The diagnostic significance of polyclonal lymphocytosis in pleural effusions. N Z Med J 2000; 113:56.</a></li><li><a class="nounderline abstract_t">Light RW, Rogers JT, Moyers JP, et al. Prevalence and clinical course of pleural effusions at 30 days after coronary artery and cardiac surgery. Am J Respir Crit Care Med 2002; 166:1567.</a></li><li><a class="nounderline abstract_t">Liu CY, Chuang SS. A Simple and Practical Guide for Triaging Lymphocyte-rich Effusions for Ancillary Studies. Adv Anat Pathol 2021; 28:94.</a></li><li><a class="nounderline abstract_t">Chu FY, Liou CB, Sun JT, et al. Eosinophilia in Pleural Effusions: a Speculative Negative Predictor for Malignancy. Asian Pac J Cancer Prev 2016; 17:1411.</a></li><li><a class="nounderline abstract_t">Fatimi SH, Deedar-Ali-Khawaja R. Catamenial pneumothorax associated with ascites, eosinophilic pleural effusion, and relatively low glucose content. Am Surg 2010; 76:E212.</a></li><li><a class="nounderline abstract_t">Mehta AA, Venkatakrishnan R, Jose W, et al. Multiple myeloma presenting as eosinophilic pleural effusion. Asia Pac J Clin Oncol 2010; 6:256.</a></li><li><a class="nounderline abstract_t">Sriratanaviriyakul N, La HH, Albertson TE. Chronic eosinophilic pneumonia presenting with ipsilateral pleural effusion: a case report. J Med Case Rep 2016; 10:227.</a></li><li><a class="nounderline abstract_t">Martínez-García MA, Cases-Viedma E, Cordero-Rodríguez PJ, et al. Diagnostic utility of eosinophils in the pleural fluid. Eur Respir J 2000; 15:166.</a></li><li><a class="nounderline abstract_t">Rubins JB, Rubins HB. Etiology and prognostic significance of eosinophilic pleural effusions. A prospective study. Chest 1996; 110:1271.</a></li><li><a class="nounderline abstract_t">Lo Cascio CM, Kaul V, Dhooria S, et al. Diagnosis of tuberculous pleural effusions: A review. Respir Med 2021; 188:106607.</a></li><li><a class="nounderline abstract_t">Takeuchi E, Okano Y, Machida H, et al. Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion. Cancer Immunol Immunother 2022; 71:365.</a></li><li><a class="nounderline abstract_t">Okimoto N, Kurihara T, Honda Y, Ohba H. Cause of basophilic pleural effusion. South Med J 2003; 96:726.</a></li><li><a class="nounderline abstract_t">Azfar Ali H, Lippmann M, Mundathaje U, Khaleeq G. Spontaneous hemothorax: a comprehensive review. Chest 2008; 134:1056.</a></li><li><a class="nounderline abstract_t">Zeiler J, Idell S, Norwood S, Cook A. Hemothorax: A Review of the Literature. Clin Pulm Med 2020; 27:1.</a></li><li><a class="nounderline abstract_t">Porcel JM, Esquerda A, Martínez M, et al. [Influence of pleural fluid red blood cell count on the misidentification of transudates]. Med Clin (Barc) 2008; 131:770.</a></li><li><a class="nounderline abstract_t">Berger HW, Mejia E. Tuberculous pleurisy. Chest 1973; 63:88.</a></li><li><a class="nounderline abstract_t">Winterbauer RH, Riggins RC, Griesman FA, Bauermeister DE. Pleuropulmonary manifestations of Waldenstrom's macroglobulinemia. Chest 1974; 66:368.</a></li><li><a class="nounderline abstract_t">Yanamandra U, Deo P, Sahu KK, et al. Clinicopathological Profile of Myelomatous Pleural Effusion: Single-center Real-world Experience and Review of Literature. Clin Lymphoma Myeloma Leuk 2019; 19:183.</a></li><li><a class="nounderline abstract_t">Duntley P, Siever J, Korwes ML, et al. Vascular erosion by central venous catheters. Clinical features and outcome. Chest 1992; 101:1633.</a></li><li><a class="nounderline abstract_t">Huggins JT, Sahn SA. Duro-pleural fistula diagnosed by beta2-transferrin. Respiration 2003; 70:423.</a></li><li><a class="nounderline abstract_t">Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med 1980; 69:507.</a></li><li><a class="nounderline abstract_t">Arnold DT, Hamilton FW, Elvers KT, et al. Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions. Am J Respir Crit Care Med 2020; 201:1545.</a></li><li><a class="nounderline abstract_t">Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum 2006; 35:368.</a></li><li><a class="nounderline abstract_t">Ahn CS, Shin JW, Kim JG, et al. Spectrum of pleuropulmonary paragonimiasis: An analysis of 685 cases diagnosed over 22 years. J Infect 2021; 82:150.</a></li><li><a class="nounderline abstract_t">Wang J, Liu J, Xie X, et al. The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions. BMC Pulm Med 2017; 17:168.</a></li><li><a class="nounderline abstract_t">Kho SS, Chan SK, Yong MC, et al. Pleural fluid lactate as a point-of-care adjunct diagnostic aid to distinguish tuberculous and complicated parapneumonic pleural effusions during initial thoracentesis: Potential use in a tuberculosis endemic setting. Respir Investig 2020; 58:367.</a></li><li><a class="nounderline abstract_t">Horowitz ML, Schiff M, Samuels J, et al. Pneumocystis carinii pleural effusion. Pathogenesis and pleural fluid analysis. Am Rev Respir Dis 1993; 148:232.</a></li><li><a class="nounderline abstract_t">Chong WH, Huggins JT, Chopra A. Characteristics of Pleural Effusion in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pneumonia. Am J Med Sci 2021; 361:281.</a></li><li><a class="nounderline abstract_t">Austin A, Jogani SN, Brasher PB, et al. The Urinothorax: A Comprehensive Review With Case Series. Am J Med Sci 2017; 354:44.</a></li><li><a class="nounderline abstract_t">Heffner JE, Brown LK, Barbieri C, DeLeo JM. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med 1995; 151:1700.</a></li><li><a class="nounderline abstract_t">Carr DT, McGuckin WF. Pleural fluid glucose. Serial observation of its concentration following oral administration of glucose to patients with rheumatoid pleural effusions and malignant effusions. Am Rev Respir Dis 1968; 97:302.</a></li><li><a class="nounderline abstract_t">Taryle DA, Good JT Jr, Sahn SA. Acid generation by pleural fluid: possible role in the determination of pleural fluid pH. J Lab Clin Med 1979; 93:1041.</a></li><li><a class="nounderline abstract_t">Good JT Jr, Taryle DA, Sahn SA. The pathogenesis of low glucose, low pH malignant effusions. Am Rev Respir Dis 1985; 131:737.</a></li><li><a class="nounderline abstract_t">Sahn SA, Reller LB, Taryle DA, et al. The contribution of leukocytes and bacteria to the low pH of empyema fluid. Am Rev Respir Dis 1983; 128:811.</a></li><li><a class="nounderline abstract_t">Maude RR, Barretti M. Severe "sweet" pleural effusion in a continuous ambulatory peritoneal dialysis patient. Respir Med Case Rep 2014; 13:1.</a></li><li><a class="nounderline abstract_t">Sahn SA, Willcox ML, Good JT Jr, et al. Characteristics of normal rabbit pleural fluid: physiologic and biochemical implications. Lung 1979; 156:63.</a></li><li class="breakAll">Sahn SA. Pleural fluid pH in the normal state and in diseases affecting the pleural space. In: The Pleura in Health and Disease, Chretien J, Bignon J, Hirsch A (Eds), Marcel Dekker, New York 1985. p.253.</li><li><a class="nounderline abstract_t">Sahn SA, Good JT Jr. Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. Ann Intern Med 1988; 108:345.</a></li><li><a class="nounderline abstract_t">Heffner JE, Heffner JN, Brown LK. Multilevel and continuous pleural fluid pH likelihood ratios for draining parapneumonic effusions. Respiration 2005; 72:351.</a></li><li><a class="nounderline abstract_t">Jiménez Castro D, Díaz Nuevo G, Sueiro A, et al. Pleural fluid parameters identifying complicated parapneumonic effusions. Respiration 2005; 72:357.</a></li><li><a class="nounderline abstract_t">Porcel JM, Valencia H, Bielsa S. Factors influencing pleural drainage in parapneumonic effusions. Rev Clin Esp (Barc) 2016; 216:361.</a></li><li><a class="nounderline abstract_t">Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117:73.</a></li><li><a class="nounderline abstract_t">Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest 2000; 117:79.</a></li><li><a class="nounderline abstract_t">Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest 2000; 117:87.</a></li><li><a class="nounderline abstract_t">Good JT Jr, Antony VB, Reller LB, et al. The pathogenesis of the low pleural fluid pH in esophageal rupture. Am Rev Respir Dis 1983; 127:702.</a></li><li><a class="nounderline abstract_t">Pine JR, Hollman JL. Elevated pleural fluid pH in Proteus mirabilis empyema. Chest 1983; 84:109.</a></li><li><a class="nounderline abstract_t">Porcel JM. Utilization of B-type natriuretic peptide and NT-proBNP in the diagnosis of pleural effusions due to heart failure. Curr Opin Pulm Med 2011; 17:215.</a></li><li><a class="nounderline abstract_t">Han ZJ, Wu XD, Cheng JJ, et al. Diagnostic Accuracy of Natriuretic Peptides for Heart Failure in Patients with Pleural Effusion: A Systematic Review and Updated Meta-Analysis. PLoS One 2015; 10:e0134376.</a></li><li><a class="nounderline abstract_t">Han CH, Choi JE, Chung JH. Clinical utility of pleural fluid NT-pro brain natriuretic peptide (NT-proBNP) in patients with pleural effusions. Intern Med 2008; 47:1669.</a></li><li><a class="nounderline abstract_t">Roberts ME, Rahman NM, Maskell NA, et al. British Thoracic Society Guideline for pleural disease. Thorax 2023; 78:s1.</a></li><li><a class="nounderline abstract_t">Yeh JH, Huang CT, Liu CH, et al. Cautious application of pleural N-terminal pro-B-type natriuretic peptide in diagnosis of congestive heart failure pleural effusions among critically ill patients. PLoS One 2014; 9:e115301.</a></li><li><a class="nounderline abstract_t">Roth BJ, O'Meara TF, Cragun WH. The serum-effusion albumin gradient in the evaluation of pleural effusions. Chest 1990; 98:546.</a></li><li><a class="nounderline abstract_t">Ogata Y, Aoe K, Hiraki A, et al. Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis? Acta Med Okayama 2011; 65:259.</a></li><li><a class="nounderline abstract_t">Biswas B, Sharma SK, Negi RS, et al. Pleural effusion: Role of pleural fluid cytology, adenosine deaminase level, and pleural biopsy in diagnosis. J Cytol 2016; 33:159.</a></li><li><a class="nounderline abstract_t">Kumar S, Agarwal R, Bal A, et al. Utility of adenosine deaminase (ADA), PCR &amp; thoracoscopy in differentiating tuberculous &amp; non-tuberculous pleural effusion complicating chronic kidney disease. Indian J Med Res 2015; 141:308.</a></li><li><a class="nounderline abstract_t">Shimoda M, Tanaka Y, Morimoto K, et al. IgG4-related pleural effusion with high adenosine deaminase levels: A case report and literature review. Medicine (Baltimore) 2021; 100:e25162.</a></li><li><a class="nounderline abstract_t">Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol 2014; 50:161.</a></li><li><a class="nounderline abstract_t">Kassirian S, Hinton SN, Cuninghame S, et al. Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis. Thorax 2023; 78:32.</a></li><li><a class="nounderline abstract_t">Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii4.</a></li><li><a class="nounderline abstract_t">Kumar SH, S S, Shetty D, Rao R. Clinicopathological Study of 117 Body Fluids: Comparison of Conventional Smear and Cell Block Technique. Curr Health Sci J 2020; 46:336.</a></li><li><a class="nounderline abstract_t">Rooper LM, Ali SZ, Olson MT. A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: a retrospective analysis of 2540 cases. Cancer Cytopathol 2014; 122:657.</a></li><li><a class="nounderline abstract_t">Abouzgheib W, Bartter T, Dagher H, et al. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. Chest 2009; 135:999.</a></li><li><a class="nounderline abstract_t">Sallach SM, Sallach JA, Vasquez E, et al. Volume of pleural fluid required for diagnosis of pleural malignancy. Chest 2002; 122:1913.</a></li><li><a class="nounderline abstract_t">Swiderek J, Morcos S, Donthireddy V, et al. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest 2010; 137:68.</a></li><li><a class="nounderline abstract_t">Thomas SC, Davidson LR, McKean ME. An investigation of adequate volume for the diagnosis of malignancy in pleural fluids. Cytopathology 2011; 22:179.</a></li><li><a class="nounderline abstract_t">Roy-Chowdhuri S, Dacic S, Ghofrani M, et al. Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology. Arch Pathol Lab Med 2020.</a></li><li><a class="nounderline abstract_t">Xu Y, Hu AY, Wang SM, et al. A retrospective analysis of pleural effusion specimens based on the newly proposed International System for Reporting Serous Fluid Cytopathology. Diagn Cytopathol 2021; 49:997.</a></li><li><a class="nounderline abstract_t">Torous VF, Pitman MB. Interpretation pitfalls and malignant mimics in cervical cytology. J Am Soc Cytopathol 2021; 10:115.</a></li><li class="breakAll">Chandra A, Crothers B, Kurtycz D, Schmitt F. The international system for serous fluid cytopathology, Springer Nature, Cham, Switzerland 2020.</li><li><a class="nounderline abstract_t">Zhang M, Yan L, Lippi G, Hu ZD. Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review. Transl Lung Cancer Res 2021; 10:1557.</a></li><li><a class="nounderline abstract_t">Schillebeeckx E, van Meerbeeck JP, Lamote K. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. Eur Respir Rev 2021; 30.</a></li><li><a class="nounderline abstract_t">Joseph J, Viney S, Beck P, et al. A prospective study of amylase-rich pleural effusions with special reference to amylase isoenzyme analysis. Chest 1992; 102:1455.</a></li><li><a class="nounderline abstract_t">Ok SJ, Kim IS, Lee EY, et al. A case of salivary-type amylase-producing multiple myeloma presenting as mediastinal plasmacytoma and myelomatous pleural effusion. Ann Lab Med 2014; 34:463.</a></li><li><a class="nounderline abstract_t">Staats BA, Ellefson RD, Budahn LL, et al. The lipoprotein profile of chylous and nonchylous pleural effusions. Mayo Clin Proc 1980; 55:700.</a></li><li><a class="nounderline abstract_t">Maldonado F, Hawkins FJ, Daniels CE, et al. Pleural fluid characteristics of chylothorax. Mayo Clin Proc 2009; 84:129.</a></li><li><a class="nounderline abstract_t">Diaz-Guzman E, Culver DA, Stoller JK. Transudative chylothorax: report of two cases and review of the literature. Lung 2005; 183:169.</a></li><li><a class="nounderline abstract_t">Toworakul C, Kasitanon N, Sukitawut W, et al. Usefulness of pleural effusion antinuclear antibodies in the diagnosis of lupus pleuritis. Lupus 2011; 20:1042.</a></li><li><a class="nounderline abstract_t">Porcel JM, Ordi-Ros J, Esquerda A, et al. Antinuclear antibody testing in pleural fluid for the diagnosis of lupus pleuritis. Lupus 2007; 16:25.</a></li><li><a class="nounderline abstract_t">Khare V, Baethge B, Lang S, et al. Antinuclear antibodies in pleural fluid. Chest 1994; 106:866.</a></li><li><a class="nounderline abstract_t">Wang DY, Yang PC, Yu WL, et al. Serial antinuclear antibodies titre in pleural and pericardial fluid. Eur Respir J 2000; 15:1106.</a></li><li><a class="nounderline abstract_t">Choi BY, Yoon MJ, Shin K, et al. Characteristics of pleural effusions in systemic lupus erythematosus: differential diagnosis of lupus pleuritis. Lupus 2015; 24:321.</a></li><li><a class="nounderline abstract_t">Chen DY, Huang YH, Chen YM, et al. ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies. Lupus Sci Med 2021; 8.</a></li><li><a class="nounderline abstract_t">Funauchi M, Ikoma S, Yu H, et al. A case of progressive systemic sclerosis complicated by massive pleural effusion with elevated CA125. Lupus 2000; 9:382.</a></li><li><a class="nounderline abstract_t">Yao X, Abd Hamid M, Sundaralingam A, et al. Clinical perspective and practices on pleural effusions in chronic systemic inflammatory diseases. Breathe (Sheff) 2020; 16:200203.</a></li></ol></div><div id="topicVersionRevision">Topic 6698 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The art of pleural fluid analysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31200818" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29157885" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Development and validation of a scoring system for the identification of pleural exudates of cardiac origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30406935" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Significance of congestive heart failure as a cause of pleural effusion: Pilot data from a large multidisciplinary teaching hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2924609" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment of congestive heart failure. Its effect on pleural fluid chemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11403751" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Influence of diuretics on the concentration of proteins and other components of pleural transudates in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28641878" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnosis and Management of Pleural Transudates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9824016" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of pleural fluid pH values obtained using blood gas machine, pH meter, and pH indicator strip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22327189" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Perception versus reality: the measuring of pleural fluid pH in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18556632" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21459855" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Blood culture bottle culture of pleural fluid in pleural infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26124314" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Procalcitonin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23570862" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22795416" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The use of pleural fluid procalcitonin and C-reactive protein in the diagnosis of parapneumonic pleural effusions: a systemic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28816982" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Performance of procalcitonin in diagnosing parapneumonic pleural effusions: A clinical study and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18222681" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27725052" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Meta-analysis of Indian studies evaluating adenosine deaminase for diagnosing tuberculous pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21439509" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Differential diagnosis of tuberculous and malignant pleurisy using pleural fluid adenosine deaminase and interferon gamma in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21227729" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evaluation of real-time polymerase chain reaction, interferon-gamma, adenosine deaminase, and immunoglobulin A for the efficient diagnosis of pleural tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26269023" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Development and Evaluation of the New Predictive Models in Tuberculous Pleuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24708530" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of same day diagnostic tools including Gene Xpert and unstimulated IFN-γfor the evaluation of pleural tuberculosis: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24386296" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Interferon-gamma release assay performance of pleural fluid and peripheral blood in pleural tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26038718" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Accuracy of the interferon-gamma release assay for the diagnosis of tuberculous pleurisy: an updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24416336" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Utility of T-cell interferon-γrelease assays for diagnosing tuberculous serositis: a prospective study in Beijing, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25994163" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Interferon Gamma Release Assays for Diagnosis of Pleural Tuberculosis: a Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33609953" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pleural fluid tumor necrosis factor for diagnosis of pleural tuberculosis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34297877" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23222247" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A diagnosis of malignant pleural mesothelioma can be made by effusion cytology:  results of a 20 year audit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33629814" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Anaplastic diffuse large B-cell lymphoma cytologically diagnosed in pleural effusion: Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34434362" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Myelomatous Pleural Effusion: A Rare Involvement in Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33629825" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lymphoreticular malignancies in serous effusions: Cytomorphologic, flow cytometric and immunocytochemical analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477860" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pleural involvement in systemic autoimmune disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21501914" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Systemic diseases and the pleura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9106577" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Primary Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24938565" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Does this patient have an exudative pleural effusion? The Rational Clinical Examination systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34774168" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pleural Fluid Analysis: Are Light's Criteria Still Relevant After Half a Century?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16626953" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bayesian analysis using continuous likelihood ratios for identifying pleural exudates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4642731" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pleural effusions: the diagnostic separation of transudates and exudates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184705" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30826806" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Simplified Criteria Using Pleural Fluid Cholesterol and Lactate Dehydrogenase to Distinguish between Exudative and Transudative Pleural Effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16716816" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Discriminating between transudates and exudates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19363209" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Biomarkers of heart failure in pleural fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18989492" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Transudates in malignancy: still a role for pleural fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9438397" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Transudative malignant pleural effusions: prevalence and mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11732649" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Useful tests on pleural fluid that distinguish transudates from exudates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32099890" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Review of interference indices in body fluid specimens submitted for clinical chemistry analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10593819" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Classic, abbreviated, and modified Light's criteria: the end of the story?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8769501" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A study of Light's criteria and possible modifications for distinguishing exudative from transudative pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23508114" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Identifying transudates misclassified by Light's criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9646981" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evaluating diagnostic tests in the pleural space. Differentiating transudates from exudates as a model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24008773" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Improving the predictive accuracy of identifying exudative effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12065357" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Multilevel likelihood ratios for identifying exudative pleural effusions(*).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796053" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A meta-analysis derivation of continuous likelihood ratios for diagnosing pleural fluid exudates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10988124" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Volume and cellular content of normal pleural fluid in humans examined by pleural lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22855161" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22307011" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Inflammation-based prognostic indices in malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33901252" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27803756" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dasatinib-induced pleural effusion: Chylothorax, an option to consider.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33753013" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cytologic findings in effusions from patients with SARS-CoV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10777226" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The diagnostic significance of polyclonal lymphocytosis in pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406850" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prevalence and clinical course of pleural effusions at 30 days after coronary artery and cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33229932" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A Simple and Practical Guide for Triaging Lymphocyte-rich Effusions for Ancillary Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27039781" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Eosinophilia in Pleural Effusions: a Speculative Negative Predictor for Malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21375820" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Catamenial pneumothorax associated with ascites, eosinophilic pleural effusion, and relatively low glucose content.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114774" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Multiple myeloma presenting as eosinophilic pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27520469" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Chronic eosinophilic pneumonia presenting with ipsilateral pleural effusion: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10678640" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Diagnostic utility of eosinophils in the pleural fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8915232" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Etiology and prognostic significance of eosinophilic pleural effusions. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34536698" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diagnosis of tuberculous pleural effusions: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34170380" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940336" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cause of basophilic pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18988781" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Spontaneous hemothorax: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33437141" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hemothorax: A Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19094877" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : [Influence of pleural fluid red blood cell count on the misidentification of transudates].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4630686" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tuberculous pleurisy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4213299" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pleuropulmonary manifestations of Waldenstrom's macroglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30704934" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Clinicopathological Profile of Myelomatous Pleural Effusion: Single-center Real-world Experience and Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1600785" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Vascular erosion by central venous catheters. Clinical features and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512681" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Duro-pleural fistula diagnosed by beta2-transferrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7424940" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Parapneumonic effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32069085" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16765714" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Rheumatoid pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33017628" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Spectrum of pleuropulmonary paragonimiasis: An analysis of 685 cases diagnosed over 22 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29202740" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32107195" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pleural fluid lactate as a point-of-care adjunct diagnostic aid to distinguish tuberculous and complicated parapneumonic pleural effusions during initial thoracentesis: Potential use in a tuberculosis endemic setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8317805" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pneumocystis carinii pleural effusion. Pathogenesis and pleural fluid analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32951846" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Characteristics of Pleural Effusion in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28755732" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The Urinothorax: A Comprehensive Review With Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7767510" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5637944" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pleural fluid glucose. Serial observation of its concentration following oral administration of glucose to patients with rheumatoid pleural effusions and malignant effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35578" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Acid generation by pleural fluid: possible role in the determination of pleural fluid pH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3923879" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The pathogenesis of low glucose, low pH malignant effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6638667" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The contribution of leukocytes and bacteria to the low pH of empyema fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26029545" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Severe "sweet" pleural effusion in a continuous ambulatory peritoneal dialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35664" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Characteristics of normal rabbit pleural fluid: physiologic and biochemical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35664" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Characteristics of normal rabbit pleural fluid: physiologic and biochemical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341671" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16088276" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Multilevel and continuous pleural fluid pH likelihood ratios for draining parapneumonic effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16088277" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pleural fluid parameters identifying complicated parapneumonic effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27161381" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Factors influencing pleural drainage in parapneumonic effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631202" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631203" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631204" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6859653" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The pathogenesis of the low pleural fluid pH in esophageal rupture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6345098" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Elevated pleural fluid pH in Proteus mirabilis empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415751" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Utilization of B-type natriuretic peptide and NT-proBNP in the diagnosis of pleural effusions due to heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26244664" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Diagnostic Accuracy of Natriuretic Peptides for Heart Failure in Patients with Pleural Effusion: A Systematic Review and Updated Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18827414" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Clinical utility of pleural fluid NT-pro brain natriuretic peptide (NT-proBNP) in patients with pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37433578" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : British Thoracic Society Guideline for pleural disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25502236" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Cautious application of pleural N-terminal pro-B-type natriuretic peptide in diagnosis of congestive heart failure pleural effusions among critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2152757" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The serum-effusion albumin gradient in the evaluation of pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860532" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27756990" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Pleural effusion: Role of pleural fluid cytology, adenosine deaminase level, and pleural biopsy in diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25963491" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Utility of adenosine deaminase (ADA), PCR&amp;thoracoscopy in differentiating tuberculous&amp;non-tuberculous pleural effusion complicating chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33726002" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : IgG4-related pleural effusion with high adenosine deaminase levels: A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24360987" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35110369" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20696692" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33717507" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Clinicopathological Study of 117 Body Fluids: Comparison of Conventional Smear and Cell Block Technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25060164" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: a retrospective analysis of 2540 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017891" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12475826" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Volume of pleural fluid required for diagnosis of pleural malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19741064" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Prospective study to determine the volume of pleural fluid required to diagnose malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20636404" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : An investigation of adequate volume for the diagnosis of malignancy in pleural fluids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32401054" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34019334" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : A retrospective analysis of pleural effusion specimens based on the newly proposed International System for Reporting Serous Fluid Cytopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32732114" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Interpretation pitfalls and malignant mimics in cervical cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32732114" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Interpretation pitfalls and malignant mimics in cervical cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33889529" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34789461" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1385051" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : A prospective study of amylase-rich pleural effusions with special reference to amylase isoenzyme analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25368822" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : A case of salivary-type amylase-producing multiple myeloma presenting as mediastinal plasmacytoma and myelomatous pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7442324" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : The lipoprotein profile of chylous and nonchylous pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19181646" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Pleural fluid characteristics of chylothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16078038" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Transudative chylothorax: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21659420" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Usefulness of pleural effusion antinuclear antibodies in the diagnosis of lupus pleuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17283581" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Antinuclear antibody testing in pleural fluid for the diagnosis of lupus pleuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8082370" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Antinuclear antibodies in pleural fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10885431" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Serial antinuclear antibodies titre in pleural and pericardial fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25318967" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Characteristics of pleural effusions in systemic lupus erythematosus: differential diagnosis of lupus pleuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34785570" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10878733" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : A case of progressive systemic sclerosis complicated by massive pleural effusion with elevated CA125.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33447289" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Clinical perspective and practices on pleural effusions in chronic systemic inflammatory diseases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
